Founded 01
2006 [CO002] Diligence report
LigaChem Biosciences
Strategically credible ADC platform with real partner validation and a larger 2026 war chest, but current public valuation already prices in substantial future success relative to disclosed revenue, current proof depth, and live execution risk.
LigaChem has a credible ADC platform and unusually strong partner validation for its stage, but the current public valuation looks stretched enough that better human proof, cleaner CMC evidence, or a cheaper entry is needed before a fresh high-conviction buy call is justified.
Cover facts
Company profile
LigaChem Biosciences is a Daejeon-based, KOSDAQ-listed clinical-stage biotech founded in 2006 and rebranded from LegoChem in 2024. The company focuses on antibody-drug conjugates using its proprietary ConjuAll™ conjugation, linker, and payload platform. Its business model has historically centered on out-licensing ADC assets and platform rights to global pharma and biotech counterparties such as Ono, SOTIO, Janssen, Iksuda, NextCure, and CStone, while selectively pulling priority assets closer to self-development after the 2026 National Growth Fund-led financing.
- Website
- www.ligachem.com
- Founded
- 2006-01-01
- Founders
- Yong-Zu Kim
- Founding location
- Daejeon, South Korea
- Headquarters
- Daejeon, South Korea
- Product
- LigaChem's product surface is an ADC platform plus a portfolio of oncology assets spanning HER2, CD19, B7-H4, CLDN18.2, LRRC15, L1CAM, and other targets across partnered and self-advanced programs.
- Customers
- Global pharmaceutical and biotechnology partners, oncology trial networks, and downstream patients reached through partner-led and occasionally self-advanced ADC development programs.
- Business model
- Licensing-led ADC platform model funded by upfronts, milestones, royalties, goods sales, and public-market financing, with a 2026 strategy shift toward selective later-stage self-development on core assets.
- Stage
- post-ipo
- Funding status
- Public evidence supports a KRW 500B CB/CPS financing in June-July 2026, meaningful historical licensing income, and a current public market cap around KRW 4.125T. Public sources do not cleanly disclose partner-level revenue splits, realized milestone conversion quality, or a fully reconciled present cash position.
Executive summary
Top strengths
- LigaChem has real ADC platform depth with multiple payload classes, active human studies, and blue-chip partner validation.
- The 2026 National Growth Fund-led financing materially improves runway and strategic flexibility versus weaker clinical-stage biotech peers.
- Licensing history and partner breadth suggest the platform is valued by sophisticated counterparties rather than by narrative alone.
- Active patents and a recognized ConjuAll™ chemistry stack provide at least some visible moat support.
Top risks
- Current lead-trial proof remains early and no posted results were retained for the active human studies cited in this report.
- The company is moving into a more capital-intensive self-development phase without public CMC or commercialization evidence strong enough to fully underwrite the shift.
- Public economics remain lumpy and partner-dependent, with limited transparency into revenue concentration, milestone timing, or future dilution risk.
- Current public valuation already implies a premium to public ADC-biotech comparables despite lower proof depth than strategic M&A precedents.
- Customer, partner, and territorial-rights complexity can slow or dilute value realization even if the underlying science remains credible.
Open gaps
- Partner-level revenue concentration, milestone waterfall timing, and royalty-conversion history.
- CMC quality metrics, supply reliability, and launch-readiness evidence for any self-developed path.
- Full freedom-to-operate and patent-landscape analysis for ConjuAll-related chemistry across key jurisdictions.
- Detailed analyst-model assumptions and scenario probabilities behind current public price targets.
- A cleaner reconciliation of present cash, per-asset spend, and runway to decisive clinical inflections.
Contents
01Company Overview
1.1 Identity, Listing Status, and Strategic Focus
LigaChem Biosciences is not a private company in the strict legal sense: official history, the company stock page, Yahoo Finance, and Stock Analysis all show that the business trades on KOSDAQ under ticker 141080, with the IPO dated to 2013. That matters because later chapters should treat it as a publicly traded biotech with venture-style economics rather than as a classic venture-backed private startup. At the same time, the operating profile still resembles a platform biotech: the company describes itself as clinical stage, Daejeon-headquartered, medicinal-chemistry-led, and focused on antibody-drug conjugates plus immuno-oncology. The March 2024 rename from LegoChem to LigaChem is important for source hygiene because older licensing and media references still use the LegoChem brand while current company pages and 2026 financing notices use LigaChem.[CO001, CO003, CO004, CO005, CO006, CO009]
| Metric | Value / Status | Date | Confidence | Gap / Caveat |
|---|---|---|---|---|
| Headquarters | Daejeon, South Korea | current | High | Seoul sales office exists in addition to HQ |
| Founded | 2006 | 2006 | High | Founder statement and market-data profiles corroborate; accessible incorporation filing not reviewed |
| Listing status | KOSDAQ 141080 | current | High | Technically public, so this report treats it as a listed startup-like biotech |
| IPO timing | 2013 KOSDAQ IPO | 2013 | Medium | Based on official history rather than exchange prospectus review |
| Current name | LigaChem Biosciences | 2024-03 | High | Older sources still use LegoChem |
| Core focus | ADC + immuno-oncology platform biotech | current | High | No direct product-revenue split disclosed on reviewed pages |
| 2026 strategic financing | KRW 500bn | 2026-06-26 | High | Post-money valuation not directly disclosed in accessible sources |
| Pre-raise cash | ~KRW 450bn | 2026-06 | High | Company figure rounded in shareholder Q&A and media summaries |
| Implied post-raise liquidity | ~KRW 900bn | 2026-06 | Medium | Derived from press summary rather than audited balance sheet |
| Commercial traction proxy | 14 global licensing deals / 8 global trials | 2026-06 | Medium | From Korea Biomedical Review summary, not a company master ledger |
Snapshot mixes official company disclosures with independent Korean biotech reporting where the company did not publish a fully consolidated KPI dashboard.
[CO003, CO004, CO005, CO006, CO009, CO013]1.2 Leadership and Governance
Leadership appears bifurcated between founder symbolism and professionalized daily management. Founder Yong-Zu Kim still presents himself as the chairman and long-term scientific architect, while the public leadership page and Yahoo profile identify Sejin Park as CEO and President. The governance page also shows that control is no longer purely founder-centric: Orion-linked executives occupy multiple internal-director seats, indicating that Pan Orion's ownership position has translated into visible board influence since becoming the largest shareholder in 2024. Governance disclosure is stronger than many Asian biotech peers because the board page names outside directors, reports attendance, and discloses meeting cadence, but it still does not provide a full English-language explanation of committee structure, reserved-matter rights, or the exact balance of influence between founder, management, and Orion representatives.[CO007, CO008, CO010, CO011, CO012]
| Person | Role | Background / constituency | Founder-market fit or functional coverage | Key-person dependency |
|---|---|---|---|---|
| Yong-Zu Kim | Chairman / founder | Founder-scientist voice and long-term strategic architect | Provides origin story, scientific continuity, and external symbolism | High |
| Sejin Park | CEO & President | Named operating chief on leadership and Yahoo profiles | Runs listed-company execution and investor-facing management | High |
| Young-Lag Cho | Chief Development Officer | Senior development executive on leadership page | Bridges pipeline into clinical development | Medium |
| Jeiwook Chae | VP, Head of R&D and CEO of ACB | Publicly named R&D leader | Connects core R&D and Boston-area subsidiary activity | Medium |
| Chul-Woong Chung | Head of ADC Research Institute | Publicly named ADC science head | Owns core modality leadership around ADC programs | Medium |
| Jinhwan Han | CTO | Publicly named technology executive | Supports platform and process development depth | Medium |
| Orion-affiliated directors | Board influence bloc | Includes In Chul Heo, Suhwon Tam, and Yong Su Kwon on governance page | Represents largest-shareholder oversight and strategic control input | Medium |
Rows enumerate the publicly disclosed founder, CEO, modality, and control figures most relevant to diligence, rather than every employee or advisor named across all company surfaces.
[CO007, CO008, CO011]1.3 Capital Formation and Market Context
The June 2026 National Growth Fund financing is the key current fact for this report. Company notices and multiple Korean news outlets align on a KRW 500 billion transaction, structured as KRW 170 billion of convertible bonds and KRW 330 billion of convertible preferred shares with long tenor. The company emphasized that the money is earmarked for R&D and late-stage clinical development, not M&A, and that out-licensing remains intact rather than displaced. That is analytically important because LigaChem is trying to add selective late-stage self-development capacity without abandoning the licensing engine that produced its existing cash reserves. The financing is also designed to look shareholder-friendly on paper: no discount, delayed conversion rights, and transfer restrictions. Even so, public-market reaction was not euphoric. NEWSTOP reported an 8.28% drop on the announcement day, which suggests the market still worries about dilution, execution, or biotech-sector fatigue despite the prestige of the state-backed capital.[CO013, CO014, CO015, CO016, CO017, CO018]
| Stakeholder | Role / entry point | Control or economic importance | Diligence ask |
|---|---|---|---|
| National Growth Fund / KDB-managed strategic fund | Lead 2026 policy-capital investor | Supplies KRW 250bn and confers national-strategic validation | Confirm voting restrictions, reserved rights, and conversion economics |
| Pan Orion | Largest shareholder and 2026 co-investor | Controls board influence and commits KRW 125bn in the 2026 financing | Reconcile current ownership percent and any control rights |
| Unnamed third financial investor | 2026 deal co-investor | Provides remaining KRW 125bn but identity and rights remain undisclosed in accessible sources | Obtain investor identity and side-letter terms |
| KOSDAQ common shareholders | Public-market float | Absorb dilution and re-rate or punish financing strategy in the stock price | Bridge fully diluted share count and free float |
| Janssen / J&J | Largest visible licensing counterparty | Potentially up to $1.7bn economics on LCB84 plus royalties | Understand probability-adjusted downstream cash capture |
| Ono Pharmaceutical and other partners | Platform and asset counterparties | Validate the recurring licensing model beyond one marquee deal | Request partner-by-partner upfront, milestone, and royalty cadence |
The map emphasizes the public control and economic perimeter rather than a full shareholder register or debt schedule, which remain undisclosed in the reviewed materials.
[CO010, CO013, CO014, CO015, CO018, CO024]Medicinal chemistry and ADC platform assets feed licensing cash, which in turn underwrites the new late-stage development ambition financed in 2026.
This diagram is causal logic, not a legal organization chart or precise cash-flow waterfall.
[CO006, CO021, CO022, CO023, CO024, CO025]Publicly disclosed financing and market markers show a well-capitalized listed biotech, but not a fully disclosed post-money valuation picture.
Liquidity, licensing-deal count, and trial count are directional because accessible public sources summarize them rather than expose a single audited dashboard.
[CO004, CO013, CO019, CO020, CO025, CO033]1.4 Partnership Engine and Milestones
LigaChem's current relevance comes less from product revenue than from the pace and size of its ADC partnering machine. The company's official history records milestone deals with Amgen, NextCure, Ono, and J&J, while independent press reports give concrete economics for the J&J/Janssen LCB84 agreement. Korea Biomedical Review adds useful scale markers by attributing 14 global licensing deals and eight global clinical trials to the company by June 2026. That partnering density helps explain why a listed Korean biotech could attract unusually large policy capital: the state fund was not financing a science project from scratch, but rather a platform with a demonstrated ability to place ADC assets into global pipelines. The 2024-2026 IND milestones for LNCB74, LCB97/ONO-7429, and LCB02A reinforce the message that the company is moving a growing set of internally originated assets through early human-development gates.[CO023, CO024, CO025, CO026, CO027, CO028]
| Date | Event | Type | Amount / valuation / status | Participants | Implication |
|---|---|---|---|---|---|
| 2006 | Founder establishes LigaChem Biosciences | founding | Company founded | Yong-Zu Kim | Origin point for later ADC platform strategy |
| 2013 | KOSDAQ IPO under 141080 | governance | Listed company status | LigaChem / KOSDAQ | Makes the company legally public, not private |
| 2019 | ConjuALL U.S. patent and Takeda-era platform licensing activity | product | Platform validation milestone | LigaChem / Takeda | Signals scalable partnerable ADC technology |
| 2022 | Amgen multi-target ADC partnership and NextCure B7-H4 ADC collaboration | partnership | Global partnering acceleration | LigaChem / Amgen / NextCure | Expands pharma relevance beyond one deal |
| 2023-12 | J&J / Janssen signs LCB84 deal | financing | Up to $1.7bn potential consideration | LigaChem / Janssen | Creates landmark external validation and cash potential |
| 2024-03 | Company renames to LigaChem; PAN Orion becomes largest shareholder | governance | Brand and control reset | LigaChem / PAN Orion | Aligns public identity and ownership with next stage |
| 2024-12 | LNCB74 receives U.S. phase 1 IND | regulatory | Clinical entry | LigaChem / NextCure | Moves a high-priority ADC toward human validation |
| 2026-04 | LCB97/ONO-7429 wins Japan phase 1 IND approval | regulatory | Clinical entry | LigaChem / Ono | Shows progress on a recently partnered ADC asset |
| 2026-05 | LCB02A wins U.S. phase 1/2 IND approval | regulatory | Clinical entry | LigaChem | Adds another internally originated ADC into the clinic |
| 2026-06-26 | National Growth Fund-led KRW 500bn financing announced | financing | KRW 500bn, no discount | LigaChem / KDB fund / Pan Orion / third investor | Funds selective late-stage self-development capacity |
This chronology combines company history with independent financing and deal coverage to show how science, licensing, listing status, and capital formation reinforce one another.
[CO002, CO005, CO009, CO010, CO013, CO024]LigaChem's public evolution runs from a 2006 founding and 2013 KOSDAQ IPO to a 2026 state-backed recapitalization around an ADC licensing engine.
Year-only or month-level dates are used where the public source did not expose a full calendar date.
[CO002, CO005, CO009, CO010, CO013, CO024]1.5 Remaining Frictions and How to Use This Baseline
For later chapters, the safest posture is to treat official company history, the stock page, the June 2026 funding notices, and corroborating Korean biotech reporting as the canonical baseline, while explicitly carrying several open gaps. The business is clearly public, ADC-focused, and better financed than most clinical-stage peers, but the exact post-money valuation of the 2026 raise is still not cleanly disclosed in accessible public materials. The unnamed third financial investor, full cap-table rights, and a precise bridge from existing cash to dilution-adjusted enterprise value remain unresolved. Public operating metrics are also uneven: liquidity is visible, but headcount, revenue mix, and the relative contribution of product sales versus licensing are not cleanly disclosed on the accessible surfaces reviewed here. That means later market, financial, and valuation chapters should rely on documented funding and pipeline progress while staying conservative on unsupported cover metrics.[CO001, CO004, CO013, CO019, CO020, CO036]
02Market Analysis
2.1 Market Boundary and What Is Actually Being Bought
For LigaChem, the relevant market is broader than the simple downstream sale of approved ADC medicines but narrower than all oncology therapeutics. The company's own materials show that its near-term monetization model remains asset licensing and co-development, which means the first buyer is usually a large pharma or biotech partner that wants access to an ADC platform, target program, or payload-linker stack. Those buyers participate in a larger end market where hospitals, oncology centers, and payers ultimately decide whether an approved ADC reaches patients. The result is a two-layer market boundary: upstream ADC partnering and development demand, and downstream ADC treatment revenue. Both matter to valuation, because a healthy end market supports licensing appetites, but total global ADC sales are not the same thing as the revenue pool directly accessible to LigaChem. This framing also prevents a common diligence mistake: equating downstream product sales with the smaller revenue pool that a pre-commercial platform developer can capture through upfronts, milestones, and royalties.[CM001, CM002, CM003, CM010, CM040]
| Segment / category | Included spend | Excluded spend | Buyer / payer | Relevance |
|---|---|---|---|---|
| Approved ADC therapeutics | Net product revenue for marketed ADC brands and related administration demand | Non-conjugated biologics and standard chemotherapy revenue | Payers and providers downstream | Largest visible end-market signal |
| ADC asset licensing | Upfronts, milestones, and royalties for platform or asset deals | Broad biotech partnering outside ADCs | Large pharma / biotech partners | Most directly relevant to LigaChem today |
| ADC clinical development | Clinical-trial and regulatory spend tied to ADC assets | General oncology R&D not linked to ADCs | Sponsors and development partners | Signals pipeline depth and future supply |
| ADC manufacturing and CDMO capacity | Conjugation, HPAPI, fill-finish, and regulatory support services | Generic biologics manufacturing capacity | Developers and outsourcing partners | Critical bottleneck for scaling supply |
The chapter treats ADCs as a two-layer market: upstream asset/platform monetization plus downstream therapy sales and administration.
[CM001, CM002, CM003, CM010, CM040]LigaChem sells first into pharma partners, but value is realized only if those assets survive reimbursement and site-of-care adoption downstream.
Flow describes economic adoption logic rather than a legal supply chain.
[CM001, CM011, CM012, CM030, CM031, CM032]2.2 Sizing Lenses and Where Demand Is Concentrated
Public ADC market estimates are directionally aligned but numerically noisy. Depending on methodology, 2026 market size ranges from about USD 16.8 billion to USD 20.3 billion, while longer-term forecasts span from the mid-USD 30 billions by 2033 to more than USD 70 billion by 2031. Rather than pretending one forecast is authoritative, the more stable conclusion is that the market is already large, is growing double digits in most published views, and remains concentrated in geographies and indications where reimbursement, biomarker testing, and oncology infrastructure are already mature. Breast cancer and HER2-linked therapies dominate today, while Asia-Pacific is the most relevant growth region for a Korean developer like LigaChem because reimbursement and domestic ADC investment are expanding in Japan, China, and South Korea. That regional growth story matters more for LigaChem than generic global TAM rhetoric.[CM004, CM005, CM006, CM007, CM008, CM009]
| Publisher | Year / horizon | Geography | Value | CAGR / growth | Methodology signal | Confidence | Limitation |
|---|---|---|---|---|---|---|---|
| Grand View Research | 2023 to 2030 | Global | USD 11.29B to USD 24.01B | 9.2% CAGR (2024-2030) | Industry revenue and segment shares | Medium | Forecast begins from 2023 not 2026 |
| Business Research Company | 2026 to 2030 | Global | USD 20.28B to USD 46.95B | 22.7% CAGR (2026-2030) | Factory-gate market sizing by application and end user | Medium | Commercial vendor methodology not fully transparent |
| Research and Markets | 2025 to 2030 | Global | +USD 13.77B | 15.7% CAGR | Forecast and vendor landscape lens | Medium | Incremental-growth framing is not directly comparable with others |
| Mordor Intelligence | 2026 to 2031 | Global | USD 20.12B to USD 71.55B | 28.88% CAGR | Proprietary model with driver and restraint weights | Medium | Very bullish relative to peer forecasts |
| Fairfield Market Research | 2026 to 2033 | Global | USD 16.80B to USD 35.99B | 11.5% CAGR | Product and region mix with access commentary | Medium | Long horizon and publisher assumptions may smooth volatility |
| Fairfield Market Research | 2026 | North America | USD 6.72B | n/a | Regional slice of global market | Medium | Region share is not a direct proxy for LigaChem SAM |
The right takeaway is a valuation range and concentration pattern, not one canonical TAM number.
[CM004, CM005, CM006, CM007, CM008, CM009]Geographic sizing layers show that the relevant ADC market is large globally and still anchored in reimbursed developed markets.
This is a constrained geography lens, not a literal TAM/SAM/SOM waterfall for LigaChem.
[CM006, CM034]Public ADC market estimates vary materially by methodology even while all point to a large and growing oncology category.
Low/mid/high pulls from different publishers rather than one internally consistent model.
[CM004, CM005, CM006, CM007, CM008, CM034]2.3 Buyers, Payers, and the Adoption Path
The downstream ADC adoption path remains institution-heavy. Hospitals dominate current administration economics, and the market reports still describe hospitals and clinics as the practical end-user channel because these therapies require infusion infrastructure, biomarker testing, safety management, and reimbursement coordination. Payer control is equally strong: NICE's Enhertu decision demonstrates that even clinically impressive ADCs can be blocked when cost-effectiveness remains above acceptable thresholds, while PADCEV's support materials remind providers that coverage varies by payer and setting and must be verified before treatment. In other words, scientific validity is necessary but insufficient; real market access depends on guideline position, formulary acceptance, and reimbursement workflow. For LigaChem, this means any partner must not only develop an asset successfully but also navigate HTA bodies, insurers, and site-of-care economics in the dominant oncology markets.[CM011, CM012, CM018, CM019, CM030, CM031]
| Segment | Buyer | User | Payer | Workflow / budget owner | Adoption trigger |
|---|---|---|---|---|---|
| ADC platform licensing | Global pharma and oncology biotechs | R&D and BD teams | Corporate R&D budget | Deal team and portfolio committee | Differentiated asset or linker-payload platform |
| Marketed solid-tumor ADCs | Hospital oncology departments | Medical oncologists and infusion teams | Insurers / national health systems | Formulary and oncology budget owners | Compelling survival or response data plus biomarker fit |
| Breast-cancer ADCs | Cancer centers and hospital systems | Breast oncologists | Public and private payers | Guideline-driven oncology budgets | HER2 or TROP2 testing and label expansion |
| Urothelial and hematologic ADCs | Specialty oncology centers | Disease-area specialists | Payers and pharmacy-benefit managers | Line-of-therapy reimbursement decisions | Approved indication and provider familiarity |
| Asia-Pacific access expansion | Local hospital networks and pharma partners | Oncology specialists | National reimbursement schemes | Public formulary and procurement bodies | Priority-review approval plus price negotiation |
Rows separate LigaChem's immediate corporate buyer from the downstream treatment channel and payer gatekeepers.
[CM011, CM012, CM030, CM031, CM032, CM035]Each ADC must pass scientific, regulatory, reimbursement, and delivery gates before revenue can scale.
Funnel is ordinal and evidence-backed, not a quantitative conversion-rate model.
[CM026, CM030, CM031, CM032]2.4 Growth Drivers, Bottlenecks, and the Modal Shift
The strongest bull case for ADCs is no longer just "targeted chemotherapy." The sector is benefiting from rising cancer incidence, rapid clinical-trial expansion, label expansions, richer biomarker pathways, and a wave of platform innovation that includes dual-payload, multispecific, and immunologically integrated constructs. Large incumbents are validating that shift: Roche, Pfizer, and other big pharma companies now treat ADCs as a core oncology platform, and Pfizer's Seagen acquisition shows how much strategic value can be assigned to established conjugate franchises. But the bottlenecks are equally real. Manufacturing remains expensive and operationally specialized; development is burdened by dose-optimization, immunogenicity, and pharmacology requirements; and reimbursement can still fail on price or evidence uncertainty. That combination makes ADCs a structurally attractive but operationally unforgiving market—favorable for differentiated platform owners like LigaChem, but only if they continue solving payload, linker, safety, and partnering execution better than peers. It also explains why simple market-growth headlines can mislead: even in a fast-growing category, only developers that can secure manufacturing slots, satisfy regulators, and clear reimbursement hurdles will convert innovation into durable economics.[CM017, CM020, CM021, CM022, CM023, CM024]
| Driver / constraint | Direction | Timing | Implication | Diligence ask |
|---|---|---|---|---|
| Rising cancer incidence and precision-oncology shift | Driver | Long term | Expands addressable patient pool for targeted therapeutics | Track label breadth and biomarker testing readiness |
| Clinical-trial volume and label expansion | Driver | Medium term | Increases number of partnerable assets and approved indications | Monitor active studies and pivotal-readout cadence |
| Dual-payload, bispecific, and immune-integrated ADC innovation | Driver | Medium term | Could widen efficacy and reduce resistance in solid tumors | Identify which platform owners control next-wave IP |
| Big-pharma M&A and portfolio commitment | Driver | Short to medium term | Raises partner appetite and validates category importance | Map who still needs external ADC assets |
| Manufacturing complexity and HPAPI bottlenecks | Constraint | Current | Limits speed, raises cost, and favors scaled players | Assess CDMO access and process robustness |
| Regulatory dose-optimization and pharmacology burden | Constraint | Current | Adds time and data requirements relative to simpler biologics | Review dose-optimization plans and safety packages |
| Reimbursement and HTA scrutiny | Constraint | Current | Can block uptake even after approval | Model payer sensitivity and price corridors |
| Substitute modalities and cheaper standards of care | Constraint | Current | Limits penetration when cost or safety trade-offs disappoint | Compare against chemo, bispecifics, and T-cell engagers |
Drivers and constraints are intentionally paired because ADCs can be strategically attractive while remaining operationally difficult.
[CM019, CM020, CM021, CM022, CM023, CM024]03Competitors
3.1 Competitive Landscape: Approved ADC Franchises, Platform Peers, and Korean Adjacent Challengers
LigaChem's competitive landscape has to be segmented by where competition occurs. The approved-product layer is led by Daiichi Sankyo/AstraZeneca's ENHERTU, Pfizer/Seagen's ADCETRIS portfolio, Gilead's TRODELVY franchise, and Astellas/Pfizer's PADCEV program. These companies are not direct sales competitors to LigaChem in the narrow current-period sense because LigaChem has no marketed drug; however, they are the most important benchmark competitors because their franchises define what pharma partners now regard as validated ADC performance. They have proof across label breadth, physician familiarity, adverse-event management, coding support, and reimbursement operations. Any global partner assessing LigaChem's pipeline or ConjuALL-style chemistry will compare its potential against those visible reference standards. A second layer consists of independent or recently independent ADC specialists such as ADC Therapeutics, Sutro Biopharma, and formerly Mersana. These peers resemble LigaChem more closely because they sell a platform, a focused pipeline, or both, and they must convince partners or investors that their chemistry or payload architecture matters enough to command durable economics. Public sources show real technical ambition in this set, but also uneven outcomes. ADC Therapeutics is commercial-stage, Sutro is still proving its next-generation platform in public markets, and Mersana lost independence via a cash acquisition. A third layer includes Korean and Asia-originated challengers such as Hanmi's bispecific ADC work and the broader China-led acceleration in ADC deal flow. That regional pressure matters because it increases the number of alternatives available to the same global partner base LigaChem courts.[CP001, CP002, CP003, CP004, CP006, CP010]
| Competitor | Category | Scale / Funding Signal | Target Segment | Key Differentiation | Key Limitation vs LigaChem or vs leaders |
|---|---|---|---|---|---|
| LigaChem Biosciences | Licensing-led ADC platform company | KOSDAQ-listed clinical-stage biotech; repeated global partnerships | ADC platform partnerships and partnered pipeline | Medicinal-chemistry-led conjugation platform and licensing track record | No marketed ADC or public downstream access infrastructure |
| Daiichi Sankyo / AstraZeneca (ENHERTU) | Approved ADC incumbent | Large-cap pharma / global oncology franchise | HER2-defined solid tumors across multiple lines | Best-selling ADC; broadest visible label expansion among cited competitors | Large-farma benchmark is hard to match; not a pure platform-comparison peer |
| Pfizer / Seagen / Takeda (ADCETRIS-led set) | Approved ADC incumbent | Big-pharma scale with acquired ADC pipeline | Hematologic malignancies and broader acquired ADC portfolio | Eight ADCETRIS indications; deep corporate resources post-Seagen deal | Less obviously comparable to LigaChem on partnering model; more commercial than platform-led |
| Gilead (TRODELVY) | Approved ADC commercial competitor | Large-cap pharma with formal oncology support stack | TROP2-driven breast-cancer franchise | Ordering data, benefits investigation, and patient financial assistance already visible | Narrower target footprint than ENHERTU; still a commercial benchmark rather than platform analog |
| Astellas / Pfizer (PADCEV) | Approved ADC commercial competitor | Global pharma support programs and payer tooling | Nectin-4 urothelial-cancer franchise | Formal copay program and payer-verification support illustrate commercialization readiness | Focus is narrower by tumor type than broad pan-solid-tumor platform narratives |
| ADC Therapeutics | Focused public ADC specialist | Commercial-stage but still small-cap-style specialist | Hematologic malignancies; anti-CD19 focus plus portfolio expansion | One FDA-approved ADC and explicit ADC-only identity | Much narrower franchise breadth than ENHERTU-scale leaders |
| Sutro Biopharma | Next-generation platform challenger | Public company centered on platform narrative | Single- and dual-payload ADCs for solid tumors | Dual-payload positioning addresses resistance and next-gen format differentiation | No comparable commercial proof or access stack disclosed publicly |
| Day One / acquired Mersana | Adverse platform case and asset challenger | Acquired 2026 for cash plus CVR; delisted | B7-H4-targeting Emi-Le and related ADC pipeline | Shows strategic value of differentiated ADC asset in rare oncology | Loss of independence is evidence that platform economics were not yet self-sustaining |
| Hanmi Pharmaceutical | Korean adjacent challenger | Regional pharma with active AACR 2026 oncology pipeline disclosure | Bispecific ADC and other next-generation oncology modalities | BH4601 shows Korea-based competition is moving into bispecific ADCs too | Public English evidence is thinner than for global leaders |
Scale/funding cells are directional because public sources mix market position, public-company status, and transaction signals rather than uniform cash data for every row.
[CP003, CP014, CP016, CP018, CP021, CP022]Ordinal view of platform differentiation versus clinical/commercial validation across the main competitors relevant to LigaChem.
Axes are evidence-backed ordinal scores from 1 to 5, not revenue or clinical-endpoint measurements. X-axis = platform differentiation; Y-axis = clinical/commercial validation.
[CP004, CP014, CP016, CP018, CP021, CP034]3.2 Competitor Profiles: Where the Benchmarks Are Strongest and Where LigaChem Actually Overlaps
The strongest commercial benchmark is ENHERTU. Official patient and HCP pages show a franchise that already spans multiple HER2-defined breast-cancer settings, NSCLC, gastric cancer, and HER2-positive solid tumors. BioMed Nexus describes it as the best-selling ADC, which matters less as a sales brag than as proof that one linker-payload system can become a platform with repeatable clinical and commercial expansion. ADCETRIS remains narrower by disease area but still matters because its official materials emphasize eight indications and more than a decade of clinical use. TRODELVY and PADCEV add a different lesson: both pair their label with clear ordering, benefits-investigation, and copay-support surfaces that demonstrate what scaled oncology commercialization looks like once an ADC wins approval. Among independent specialists, ADC Therapeutics is the clearest public peer that has reached commercialization, though its focus is narrower and more hematology-heavy than the broad solid-tumor ambitions surrounding ENHERTU. Sutro competes through platform claims about single- and dual-payload engineering rather than through current commercial heft. Mersana provides the most important adverse case: even with a differentiated B7-H4 ADC and an additional pipeline, it exited the market through acquisition and delisting rather than by compounding into a durable standalone winner. Hanmi deserves attention as a Korean adjacent challenger because its AACR 2026 disclosures show a willingness to pursue bispecific ADC designs, which means LigaChem cannot assume home-region scarcity of modality innovation. The overlap is therefore real, but it is concentrated in platform credibility, next-generation chemistry, and partner attention rather than in direct product promotion today.[CP004, CP005, CP008, CP011, CP012, CP014]
| Buying criterion | LigaChem | ENHERTU / Daiichi-AZ | ADCETRIS / Pfizer-Seagen | ADC Therapeutics | Sutro | Hanmi |
|---|---|---|---|---|---|---|
| Approved marketed ADC today | No | Yes — multiple HER2 indications | Yes — 8 lymphoma indications on cited patient page | Yes — one FDA-approved anti-CD19 ADC | No public marketed ADC on cited source | No marketed ADC confirmed in cited source |
| Visible reimbursement / support infrastructure | Partner-dependent; not publicly shown on company site | Partial from HCP/patient site; full net pricing still not public | HCP site and safety-management surface visible | Unknown from cited public sources | Unknown from cited public sources | Unknown from cited public sources |
| Platform / chemistry differentiation claim | Yes — next-generation ADC platform and medicinal-chemistry emphasis | Yes — clinically validated linker-payload family | Yes — established MMAE/val-cit archetype and long clinical use | Yes — focused ADC portfolio and expansion strategy | Yes — single- and dual-payload cell-free platform | Yes — bispecific ADC modality disclosed at AACR 2026 |
| Breadth across tumor settings | Partnered and clinical-stage; breadth not yet commercial | Very broad among cited set | Moderate; lymphoma-focused in cited material | Narrower hematology focus in cited material | Early and platform-led in cited material | Early and preclinical/discovery-oriented in cited material |
| Evidence of standalone commercial durability | Unproven | Strongest in cited set | Strong in hematology niche | Partial | Unproven | Unproven |
This matrix compares public evidence, not internal capabilities. Unknown means no clean public support was retained for that cell.
[CP005, CP008, CP010, CP012, CP014, CP016]Capability coverage across six competition criteria. Unknown cells reflect missing public evidence, not confirmed absence.
The map uses qualitative values because public evidence is not uniform enough for numeric scoring on every criterion.
[CP013, CP014, CP016, CP021, CP030, CP034]3.3 Capability, Pricing Structure, Distribution Power, and Switching Costs
Capability comparisons are asymmetric because approved incumbents and platform licensors solve different jobs. For ENHERTU, ADCETRIS, TRODELVY, and PADCEV, public evidence covers labels, warnings, packaging, access support, and treatment workflows. For LigaChem, the public surface instead highlights chemistry focus and partnership orientation. That means a simple feature matrix must mark several cells as unknown rather than pretending the company already has downstream capabilities it has not disclosed. The cleanest apples-to-apples comparison is not net price per course of therapy, which is not consistently public, but contract structure. LigaChem seeks upfronts, milestones, and royalties from partners; the incumbents monetize approved vials and then reinforce utilization through reimbursement and patient-support programs. Distribution power therefore sits overwhelmingly with large-pharma incumbents. They control oncologist relationships, coverage resources, coding guidance, field reimbursement teams, and manufacturing supply chains. LigaChem's model avoids the need to build that stack immediately, which is a capital advantage, but it also leaves bargaining leverage with partners that already own commercial infrastructure. Switching costs after a partner selects an ADC platform are real because process know-how, translational datasets, and manufacturing workstreams become asset-specific. But before signature, multi-homing is likely high: public market and landscape sources show a crowded field of vendors, China-originated assets, and multiple ways for big pharma to source ADC capability. LigaChem's competitive problem is thus to become sufficiently differentiated that a partner stops treating it as one option among many chemistry suppliers.[CP013, CP022, CP023, CP026, CP027, CP028]
| Competitor | Public price / contract model | Packaging or included capability | Discount / support signal | Implication for LigaChem |
|---|---|---|---|---|
| LigaChem Biosciences | Licensing contract model: upfronts, milestones, royalties; no marketed therapy price disclosed | Platform partnership rather than patient-facing distribution | Unknown public royalty schedule; economics not fully disclosed | Competes upstream for partner economics, not downstream vial utilization today |
| ENHERTU | Public net price not disclosed on retained pages | Broad HCP and patient indication set; repeated administration model on official pages | Coverage exists but exact rebate/discount terms not public in retained sources | Benchmark proves that broad label expansion can support a franchise once access hurdles are solved |
| ADCETRIS | Public net price not disclosed on retained pages | Eight indications and extensive safety-management content on patient/HCP pages | Support and coding detail exist, but normalized price transparency remains limited | Shows mature ADC commercialization can coexist with substantial toxicity-management burden |
| TRODELVY | Public net price not disclosed; HCP access page exposes coverage-support workflow | 180 mg single-dose vial; benefits investigation and prior-auth assistance | Financial assistance and uninsured-patient support explicitly disclosed | Commercial rivals add value through patient-support operations that LigaChem currently outsources to future partners |
| PADCEV | Public net price not disclosed; support materials emphasize coverage verification | Commercial support page links coding, coverage, and copay workflow | Commercial copay assistance up to $25,000/year disclosed | Approved competitors often compete on access services even where list pricing remains opaque |
The public web surface is much better for support-program design than for net realized pricing. This is why the table centers contract model and packaging evidence rather than pretending clean price comparability exists.
[CP002, CP011, CP012, CP013, CP030]3.4 Moat Durability and Adverse Competitive Evidence
The strongest case for LigaChem's moat is that repeated licensing activity suggests outside companies view its conjugation and chemistry capabilities as credible. But the moat remains only partially validated in the public record because it has not yet been translated into a marketed in-house franchise or into the kind of multi-indication label expansion visible at ENHERTU. Public evidence shows that the sector is already crowded with approved products across many targets, and that big pharma has become comfortable acquiring or partnering for de-risked assets at scale. That helps a company like LigaChem when it has compelling data; it hurts when buyers can play multiple asset sources against each other. Adverse evidence is unusually important in this chapter. Mersana's takeout shows that a differentiated ADC platform can still end up sold rather than compounded independently. The small-cap positioning of ADC Therapeutics and Sutro relative to the pharmaceutical groups that dominate approved ADCs suggests investors remain skeptical that standalone ADC specialists will capture franchise-level economics without broader proof. Meanwhile, all approved leaders still carry significant safety burdens, and BioMed Nexus underscores that manufacturing capacity remains difficult and specialized. Taken together, these signals imply that LigaChem's competitive durability will be won or lost less on generic claims about ADC promise and more on whether its platform keeps producing partnerable assets faster, cleaner, or more economically than a crowded field of global alternatives.[CP018, CP019, CP024, CP025, CP031, CP032]
| Moat claim | Threat | Severity | Why this matters now | Mitigation / diligence ask |
|---|---|---|---|---|
| Repeatable ADC chemistry can command repeated licensing deals | Big pharma can source multiple external ADC assets and platforms in parallel | High | Crowded vendor landscape lowers single-platform bargaining power pre-deal | Demonstrate target-by-target or deal-by-deal outperformance, not generic ADC promise |
| Regional chemistry reputation is a barrier | China-originated and Korean adjacent programs are increasing the supply of partnerable ADC assets | High | Partner alternatives are broadening across Asia in 2026 | Quantify why LigaChem's linker-payload or target-selection data are superior |
| Platform ownership creates durable standalone value | Mersana acquisition and delisting show differentiated platforms can still lose independence | High | Adverse peer outcomes directly pressure valuation assumptions | Demand hard evidence on late-stage readouts and partner economics |
| Commercialization can be deferred to partners | Partners capture distribution and pricing power if LigaChem never builds downstream stack | Medium-High | Access-support programs are now visible sources of competitive advantage | Clarify which assets are destined for self-development versus perpetual out-licensing |
| ADC science itself is the moat | Approved leaders already own the strongest clinical validation, while safety and manufacturing remain hard for everyone | Medium-High | Modality novelty alone is insufficient in a 23-approved-product market | Track clinical differentiation, manufacturability, and safety window with explicit external benchmarks |
Every row ties a public moat claim to an external threat signal. None of the mitigations can be closed with marketing language alone; they require data or more contract detail.
[CP019, CP025, CP027, CP032, CP033, CP034]Compact view of the public metrics or directional signals that best summarize LigaChem's competitive durability challenge.
Values use either exact cited figures or evidence-backed directional labels where exact figures are not publicly comparable.
[CP018, CP019, CP023, CP030, CP034, CP038]04Financials
4.1 Revenue Model: High-Margin Licensing, Not Yet Recurring Product Economics
LigaChem already reports meaningful revenue, but the revenue mechanism remains much closer to platform monetization than to a conventional biopharma commercial model. Official 2025 consolidated statements show KRW 141.553 billion of revenue, with KRW 121.161 billion coming from licence fee income and only KRW 20.392 billion from goods sales. That mix matters: it means the company has demonstrated an ability to turn scientific partnerships into cash, yet the dominant line item depends on milestone timing, partner decisions, and contract recognition rather than on recurring prescription demand. The Ono package deal illustrates the structure. The company disclosed potential economics of up to $700 million plus royalties, and the July 2026 LCB97 milestone shows how revenue or cash can step up sharply when a partner advances a program. This model should not be read as low-quality in an absolute sense, because licensing income can carry excellent incremental margins and validates external demand for the platform. It should, however, be read as low-predictability revenue. There is no clean public disclosure of partner concentration, milestone schedules, or royalty ladders by asset. Goods sales appear real and ongoing, but management and third-party profiles make clear that they are secondary to the ADC licensing engine. Investors therefore need to distinguish between top-line size and top-line repeatability: LigaChem has already built a monetization engine, but it is still a deal-driven one.[CI001, CI002, CI003, CI004, CI024, CI025]
| Revenue stream | Mechanism | Unit | Current value / status | Revenue quality | Diligence ask |
|---|---|---|---|---|---|
| Licence fee income | Upfronts, milestones, or other licensing revenue from partnered programs | KRW / period | KRW 121.161 billion in 2025 | High margin but lumpy; depends on partner behavior and milestone timing | Disclose partner concentration and milestone schedule by asset |
| Goods sales | Medical device and supplies revenue | KRW / period | KRW 20.392 billion in 2025 | More repeatable than milestones but strategically underexplained | Clarify product mix, margin, and growth outlook of goods line |
| Ono milestone receipts | Clinical-triggered cash payments under LCB97 deal | Per event | July 2026 milestone >10% of 2025 revenue; exact amount confidential | High-quality cash when triggered but unpredictable timing | Provide milestone ladder and event definitions |
| Future royalties | Percentage of net sales after partnered commercialization | % of partner net sales | Not yet disclosed or realized publicly | Potentially durable, but timing and rate opaque | Disclose royalty bands and retained rights by major deal |
| Self-commercialized product revenue | Direct sales if LigaChem advances priority assets in-house | Drug sales / vial revenue | None yet | Not current; would change business model materially | Clarify which assets are intended for self-commercialization versus out-licensing |
For this company, revenue quality is determined less by whether revenue exists and more by how repeatable and partner-diversified it is.
[CI001, CI002, CI003, CI004, CI024, CI025]| Price / contract model | List vs realized pricing | Discounts / unknowns | Source | Implication |
|---|---|---|---|---|
| Licence fee income under partnered deals | Realized as accounting revenue when milestones or contract terms permit recognition | Deal-specific timing and revenue-recognition rules not disclosed publicly | Official 2025 financial statements | Top line can spike without implying recurring demand |
| Ono LCB97 package deal up to $700 million plus royalties | Maximum package value, not realized cash today | Actual upfront, milestone timing, and royalty rates not fully public | Official Ono deal press release | Commercial potential exists, but forecastability remains limited |
| July 2026 LCB97 milestone payment | Realized cash event tied to first patient dosing | Exact amount confidential; public estimate uses >10% of prior-year revenue floor | Sedaily milestone article + disclosure list | Milestones can support liquidity before royalties arrive |
| Goods sales | Product or supply sales rather than licensing | Realized pricing and gross margin not disclosed | Official financial statements + Yahoo profile | Only modest evidence of recurring non-licensing revenue |
| 2026 CB/CPS financing | Capital, not revenue; conversion price KRW 149,300 per share per BigGo | No-discount issuance disclosed, but dilution path depends on conversion and future stock price | Official Q&A + BigGo + WOWTALE | Improves liquidity while embedding future conversion sensitivity |
This chapter separates monetization contracts from financing. The company has both, but they solve different problems.
[CI018, CI020, CI024, CI025, CI026]How ADC platform activity converts into reported revenue and eventual cash generation for LigaChem.
Nodes combine official current-state metrics with public contract structures; this is a business-model bridge, not an accounting ledger.
[CI001, CI002, CI024, CI025, CI027]4.2 Cost Structure and Unit Economics: Gross Margin Looks Strong, Operating Model Does Not
The public cost structure shows why LigaChem cannot yet be judged on traditional earnings power despite its unusually large reported revenue for a clinical-stage biotech. Official 2025 statements show KRW 248.039 billion of operating expense, including KRW 216.908 billion of R&D expense, against an operating loss of KRW 106.486 billion. In other words, the company spent far more on research and development than it generated in total revenue. Yahoo's gross-profit line looks superficially attractive because licence fees carry relatively little classical cost of revenue, but that is only one layer of the economics. The more important question is how much incremental scientific and clinical spending is needed to keep future milestones coming. That is why classic SaaS-style unit metrics such as CAC or payback do not fit the business. The practical monetization unit here is the deal, the program, or the milestone, not a recurring subscription or transaction cohort. A more useful financial lens is revenue quality versus development intensity: high gross margin on recognised licence income, but very high R&D intensity and large operating losses as the company pushes assets deeper into development. Goods sales may offer some steadier revenue, yet their margin profile and strategic importance are not disclosed clearly enough to anchor the investment case. The result is an operating model that can look efficient at the gross-profit layer while still remaining capital-intensive and fragile at the cash-flow layer.[CI005, CI006, CI007, CI008, CI013, CI028]
| Metric | Value / status | Confidence | Why it matters | Diligence ask |
|---|---|---|---|---|
| Licence fee share of 2025 revenue | ~86% | Medium | Shows top line is dominated by deal economics, not product sell-through | Reconcile by partner and by one-time vs ongoing recognition |
| R&D as % of 2025 revenue | ~153% | Medium | Shows self-funding has not been reached | Break down by asset and by outsourced vs internal spend |
| Operating loss 2025 | KRW 106.486 billion | High | Confirms current model is loss-making despite large reported revenue | Provide monthly cash burn and loss bridge into 2026 |
| Operating cash flow 2025 | -KRW 124.533 billion | High | Best public burn proxy before the new financing | Provide quarterly operating cash flow for 2026 after the raise |
| Goods-sales margin | Unknown | Low | Could be the most repeatable revenue line if meaningful | Disclose margin and strategic role of goods line |
The most decision-useful metrics are burn, partner dependence, and per-program spend. Traditional SaaS metrics are not appropriate here.
[CI003, CI005, CI006, CI007, CI009, CI028]Publicly visible financial bridge from revenue to burn.
All numeric values are public 2025 figures unless explicitly labeled as qualitative.
[CI001, CI005, CI006, CI008, CI009]4.3 Capital Adequacy: Sub-12-Month Runway on 2025 Burn, Then a Transformational 2026 Raise
Before the 2026 financing, the public figures pointed to a company that was materially dependent on outside capital. Official and Yahoo-based cash-flow pages both show 2025 operating cash outflow of about KRW 124.533 billion and year-end cash of about KRW 98.650 billion. On that simple basis, LigaChem was carrying less than a year of runway. The 2026 recapitalization changed that picture dramatically. Official Q&A and multiple external reports describe a KRW 500 billion financing split between KRW 170 billion of convertible bonds and KRW 330 billion of convertible preferred shares, explicitly designed to fund R&D and late-stage development rather than M&A. Public reports also describe conversion constraints, a no-discount issuance, and substantial participation from state-backed capital plus Pan Orion. Even so, capital adequacy is not fully settled by the headline size of the round. Public sources disagree sharply on current cash, with figures ranging from roughly KRW 60.7 billion to KRW 418 billion or even about KRW 450 billion depending on source and definition. The discrepancy likely reflects different cut dates or whether the figure includes broader liquid resources, but it makes exact runway calculation impossible from public materials alone. In addition, the strategic shift toward more self-development means 2025 burn is probably a floor, not a ceiling. The raise clearly buys time; it does not eliminate future financing risk if multiple assets are advanced in-house at once.[CI009, CI010, CI011, CI014, CI017, CI018]
| Item | Public value / range | Confidence | Why it matters | Diligence ask |
|---|---|---|---|---|
| End-2025 cash and equivalents | KRW 98.650 billion | High | Baseline liquidity before the 2026 raise | Verify audited 2025 year-end cash and restricted-cash treatment |
| 2025 operating cash burn | -KRW 124.533 billion | High | Shows stand-alone runway was below one year | Confirm Q1/Q2 2026 burn after financing |
| 2026 financing size | KRW 500 billion | High | Transformational liquidity event | Reconcile cash receipt timing and use of proceeds by tranche |
| 2026 financing structure | KRW 170 billion CB + KRW 330 billion CPS | High | Defines dilution and maturity profile | Provide full conversion and lock-up schedule |
| Current cash / liquid resources in 2026 | Conflicting public figures: ~KRW 60.7b, KRW 418b, or ~KRW 450b | Medium | Blocks a precise runway calculation | Publish a treasury bridge with definitions |
| Next-round trigger | Likely tied to pace of self-development and late-stage trial spend, not immediate solvency | Medium | Capital needs may reappear sooner if internal programs accelerate | Disclose asset-by-asset capital plan through 2028 |
Capital adequacy clearly improved in 2026, but exact runway still depends on how management defines available capital and how aggressively it self-develops core assets.
[CI009, CI010, CI011, CI017, CI018, CI019]Publicly supportable bounds for key financial inputs and runway interpretation.
Low/base/high ranges combine directly reported values with explicitly labeled interpretive bounds where public sources conflict.
[CI010, CI011, CI017, CI033, CI035, CI036]How public capital sources and planned uses map onto LigaChem's strategy shift.
This map shows funding logic rather than audited cash timing. It combines official statements with external reporting on term structure.
[CI017, CI020, CI022, CI023, CI032, CI036]4.4 Financial Verdict and Remaining Underwriting Blockers
The public verdict is mixed but intelligible. LigaChem already has a real external monetization engine: it can sign licensing deals, earn milestone-triggered cash, and report large licence-fee revenue relative to many early-stage peers. That is a material positive because it separates the company from purely pre-revenue platform stories. At the same time, the model is not yet self-sustaining. Operating losses are large, operating cash flow is negative, and the strategic move toward selective late-stage self-development increases the chance that future capital needs rise rather than fall. The market capitalization and analyst targets shown on Yahoo also suggest investors are valuing pipeline optionality, not near-term cash generation. The underwriting blockers are therefore specific, not generic. Investors still lack partner-level revenue concentration, per-program R&D budgets, realized royalty ladders, clean current-cash reconciliation, and a precise view of how much of the 2026 capital will be consumed by each self-development asset. Those gaps matter more than another generic statement that ADC is a promising field. With them, one could build a serious model of runway, dilution risk, and quality of earnings. Without them, the best public conclusion is that LigaChem moved from financially pressured to financially extended in 2026, but not from uncertain to predictable.[CI030, CI031, CI032, CI033, CI034, CI037]
| Missing private metric | Impact on analysis | Exact diligence path |
|---|---|---|
| Current cash reconciliation | Prevents clean runway math | Obtain treasury bridge for cash, equivalents, short-term financial assets, and post-close proceeds |
| Partner-by-partner revenue concentration | Prevents revenue-quality underwriting | Request revenue split and milestone schedule by major counterparty |
| Per-program R&D budget | Prevents burn forecasting by asset | Request program budgets, CRO commitments, and manufacturing spend by pipeline asset |
| Royalty and milestone ladders | Prevents valuation of future licensing economics | Review deal summaries and board-approved contract attachments |
| Goods-sales segment economics | Prevents assessment of the only visible recurring non-licensing line | Request segment-level margin and management commentary |
These are not cosmetic gaps. They determine whether the company is merely extended by new capital or actually funded through meaningful value-inflection points.
[CI029, CI031, CI033, CI034, CI039]05Product & Technology
5.1 What the Product Actually Is: A Platform-plus-Pipeline ADC Company
LigaChem's product is best understood as a technology stack plus a portfolio, not as a single commercial drug. Official company pages define the business around next-generation ADCs and medicinal chemistry, while the pipeline pages show a broad menu of target-payload combinations rather than one flagship module. In customer workflow terms, the first customer is often a pharma or biotech partner that wants access to a target-ready candidate or to the conjugation engine behind it. The second downstream customer is the clinical network that must operationalize biomarker-positive trial enrollment, dose scheduling, and eventual commercialization. This is why the company can report platform partnerships, product-specific licenses, and internally advanced assets at the same time. The product map is already fairly broad. Public materials show HER2-MMAF, CD19-pPBD, B7H4-MMAE, CLDN18.2-Topo1i, LRRC15-MMAE, and additional bispecific or solid-tumor programs, which means the company is expressing its platform through multiple biological targets and multiple payload classes. That breadth is important because it suggests the company is selling a repeatable chemistry-and-development capability. But the product definition remains pre-commercial: the company is still proving whether these assets can graduate from architecture and early clinical design into durable, marketed oncology products.[CE001, CE002, CE003, CE004, CE014, CE037]
| Asset / module | Primary user | Status / maturity | Differentiation | Diligence gap |
|---|---|---|---|---|
| LCB02A (CLDN18.2-Topo1i) | Oncology trial sites / future partner or in-house team | Phase 1/2 recruiting | CLDN18.2 target plus Topo1 payload; self-advanced by LigaChem | No posted efficacy results yet |
| LNCB74 (B7-H4 ADC) | Oncology trial sites / NextCure collaboration context | Phase 1 recruiting | B7-H4 target; toxicity-reduction positioning | No public results; partner-side proof still early |
| IKS014 / LCB14 (HER2-MMAF) | Iksuda global development network | Phase 1 recruiting | HER2 targeting with MMAF and site-specific linker characterization | Comparative superiority claims are company-authored |
| IKS03 / LCB73 (CD19-pPBD) | Iksuda hematology trial network | Phase 1 recruiting | CD19 target with PBD payload | No human efficacy data posted |
| SOT106 (LRRC15-MMAE) | SOTIO pre-IND development team | Pre-IND with H2 2026 IND plan | ConjuAll-derived LRRC15 program with preclinical outperformance claims | Human readiness and CMC proof not public |
| LCB36 (CD20xCD22-pPBD) | Future in-house / partner hematology workflow | IND planned per 2026 roadmap summary | Bispecific blood-cancer orientation broadens platform modality | Only roadmap-level public evidence retained |
| LCB58A (CEACAM5) | Future in-house / partner solid-tumor workflow | Global trials planned next year per roadmap summary | Extends platform into another solid-tumor target family | Only roadmap-level public evidence retained |
Asset maturity is strongest on trial registration and weakest on posted human readouts.
[CE004, CE005, CE007, CE009, CE012, CE015]LigaChem's delivered product is a layered ADC stack rather than a single feature or drug.
[CE002, CE010, CE013, CE014, CE021]5.2 Architecture and Operating Workflow
The public architecture is unusually legible for a biotech because the company and trial records expose the major design components. Official materials say the ConjuAll stack is differentiated by site-specific conjugation, linker stability, toxin release, and pharmacokinetic profile. Clinical-trial APIs then show how that philosophy is instantiated differently across assets: LCB02A couples a CLDN18.2 antibody to a Topo1 inhibitor payload; IKS014 / LCB14 is a HER2-targeting MMAF ADC; IKS03 / LCB73 uses a CD19 antibody with a PBD pro-drug; and LNCB74 is a B7-H4-targeted ADC in 21-day IV cycles. This is a real product architecture, not a generic marketing slogan. The operating workflow is long and multi-stage. A target and antibody are selected, the conjugation and payload design are tuned, preclinical evidence is generated, and then biomarker-gated clinical trials move through dose escalation, dose expansion, and eventual partner or self-development decisions. The workflow is global rather than local: cited studies recruit across the U.S., Australia, Singapore, Canada, Europe, and Korea. At the same time, the model remains partner-dependent. SOT106 is explicitly described as partner-led for development, manufacturing, and commercialization, while the Iksuda investment shows LigaChem sometimes deepens control through equity and governance rather than by internalizing every function itself.[CE002, CE006, CE010, CE011, CE013, CE014]
| User job | Current workflow | LigaChem solution | Measurable benefit | Limitation |
|---|---|---|---|---|
| Pharma partner wants an ADC candidate against a chosen target | Select antibody / target, negotiate access, develop or license candidate | Provide platform-derived candidate or platform license | Accelerates access to multi-payload ADC architecture | Partner economics and milestone timing stay opaque |
| Trial site wants biomarker-positive refractory patients | Screen for target expression, confirm organ function, dose in cycles | Provide protocol-defined ADC with target-specific eligibility criteria | Enables targeted enrollment rather than unselected chemotherapy | Workflow remains slow and site-intensive |
| Partner wants to advance solid-tumor candidate globally | Use ConjuAll-derived asset with partner-led IND/Phase 1 path | Examples include SOT106, IKS014, LNCB74 | Global site deployment already visible for multiple assets | Commercialization often leaves LigaChem dependent on partner execution |
| LigaChem wants to increase in-house option value | Use new capital to retain or self-advance priority assets later | LCB02A, LCB36, LCB58A highlighted in 2026 roadmap reports | Creates optionality beyond early out-licensing | Raises execution and burn complexity |
The same platform can serve different workflows: pure licensing, joint development, or direct self-advancement.
[CE003, CE016, CE017, CE020, CE021, CE032]| Layer / component | Role | Dependency | Risk |
|---|---|---|---|
| Targeting antibody | Defines tumor recognition and internalization entry point | Internal discovery or external antibody partner | Target heterogeneity or weak internalization can erode efficacy |
| ConjuAll conjugation / linker layer | Attaches payload and manages stability plus release | Chemistry know-how and IP durability | Public patent depth and CMC reproducibility not well disclosed |
| Payload layer (MMAF, MMAE, pPBD, Topo1i) | Provides cytotoxic mechanism | Payload-specific safety window and tumor biology | Class toxicity can force narrow eligibility or dose limits |
| Clinical operating layer | Dose escalation, biomarker gating, response measurement, global sites | Investigators, regulators, partner operations | No posted results yet for lead trials |
| Partner / commercialization layer | Funds, manufactures, or commercializes many assets | Partner commitment and trial execution | LigaChem may lack direct control over downstream success |
The public architecture is strongest on molecule design and weakest on disclosed CMC and manufacturing implementation.
[CE002, CE010, CE013, CE014, CE021, CE029]How a platform concept becomes a patient-facing clinical asset.
[CE003, CE021, CE022, CE037]The product stack depends on several external and internal gates simultaneously.
[CE016, CE020, CE029, CE030, CE038]5.3 Maturity, Roadmap, and Dependency Structure
The maturity picture is mixed but improving. LCB02A is already in a first-in-human Phase 1/2 design with 191 planned subjects and a projected multi-year timeline. LNCB74 is recruiting in Phase 1. IKS014 and IKS03 are both in global Phase 1 programs under Iksuda. SOT106 remains pre-IND but has a publicly stated second-half-2026 IND objective. BigGo and other 2026 coverage add another layer by describing LCB36 and LCB58A as next programs to be accelerated as LigaChem pushes beyond pure out-licensing. This gives the company unusual breadth for a clinical-stage ADC platform, but it also increases execution dependency because many programs now compete for capital, management attention, and manufacturing planning. The platform's critical dependencies are clear. Biomarker assays and patient-selection logic are essential, because the trials are built around target-positive populations. Partners matter because much of downstream development and commercialization still sits outside LigaChem. Regulators and trial sites matter because none of the lead assets have posted mature results yet; they are still design-stage or early-recruitment stories. And manufacturing matters even when public details are sparse, because payload-linker quality and CMC reproducibility are fundamental to the class. The roadmap is therefore exciting, but it is not yet de-risked.[CE005, CE007, CE009, CE012, CE015, CE016]
| Date / stage | Milestone | Status | Implication | Source |
|---|---|---|---|---|
| 2025-01 actual | LNCB74 Phase 1 start | Completed / ongoing recruitment | B7-H4 program is in human testing | ClinicalTrials API + NextCure |
| 2026-03 posted / 2026-08 est. | LCB02A Phase 1/2 global study start | Recruiting / launch year | CLDN18.2 self-advanced program moves from concept to clinical execution | ClinicalTrials API |
| 2026 H2 planned | SOT106 global IND filing | Planned | Partner-derived LRRC15 program tests platform portability | LigaChem press release |
| 2026-07 confirmed dosing milestone | LCB97 first patient dosing under Ono | Completed milestone | Shows platform still generating downstream program progress | Sedaily milestone |
| 2026 roadmap summary | LCB36 IND plan for next year | Planned | Signals bispecific/hematology expansion | BigGo |
| 2026 roadmap summary | LCB58A global clinical start next year | Planned | Signals broader solid-tumor expansion | BigGo |
Roadmap proof is strongest when tied to registered trials or dated partner milestones and weakest for next-wave pipeline items described only in roadmap reporting.
[CE005, CE007, CE009, CE015, CE022, CE032]Public evidence shows broad architecture but uneven maturity across assets.
[CE005, CE007, CE009, CE012, CE015, CE032]5.4 Trust, Safety, and Quality Controls
The strongest trust signal in public sources is not certification but protocol discipline. ClinicalTrials materials show FDA-regulated studies, explicit dose-escalation and dose-expansion structures, objective response metrics such as RECIST or Lugano, ECOG performance requirements, organ-function thresholds, and product-specific exclusion criteria. LNCB74 excludes prior MMAE-ADC exposure, ILD/pneumonitis history, neuropathy, and corneal disease. LCB02A excludes prior Topo1 ADC exposure. IKS014 excludes ILD/pneumonitis and clinically significant ocular abnormalities. These are concrete signs that the company and its partners understand class-specific safety liabilities and are designing around them. But there are still important trust gaps. No public manufacturing certifications, batch-release metrics, supply reliability statistics, or posted clinical results were retained for the cited assets. Reviews of the broader field continue to emphasize toxicity, heterogeneity, resistance, and complex manufacturing as unresolved constraints on ADC success. That means LigaChem's trust case is presently strongest at the trial-design and scientific-rationale level, weaker at the manufacturing-quality and market-reliability level. The product-tech diligence question is therefore not whether there is a real platform—there is—but whether public proof is deep enough yet to underwrite durable scale and consistent execution.[CE023, CE024, CE025, CE026, CE027, CE029]
| Control / quality signal | Status | Scope | Gap |
|---|---|---|---|
| ClinicalTrials registration | Present | LCB02A, LNCB74, IKS014, IKS03 | Registration proves governance, not efficacy |
| FDA-regulated-drug flag | Present in cited trial APIs | Current human studies | Does not substitute for manufacturing-quality disclosure |
| Standardized response / safety frameworks | Present | RECIST, Lugano, ECOG, organ-function screening, adverse-event collection | No public mature output data yet |
| Class-specific exclusion criteria | Present | ILD/pneumonitis, prior payload exposure, neuropathy, ocular risk | Shows risk awareness but also underlines narrow safety window |
| Manufacturing and QA metrics | Not publicly retained | CMC, GMP, batch release, deviation history | Major diligence blocker for platform underwriting |
Public trust evidence is currently protocol-centric rather than commercialization- or manufacturing-centric.
[CE023, CE024, CE025, CE026, CE029, CE038]06Customers
6.1 Who the Customers Are: Counterparties, Not End Users
LigaChem's present customer base is best viewed through a biotech licensing lens. The company is not yet selling finished drugs to hospitals, payers, or consumers. Instead, it sells access to an ADC platform, to individual product candidates, or to co-development rights. Official company materials explicitly define the partner model around joint research, co-development, and licensing. That makes the customer definition unusually clear: the direct buyers are pharma and biotech organizations willing to pay for exclusive rights, the direct users are partner R&D and clinical-development teams that carry assets forward, and the economic payers are the same counterparties through upfront fees, milestones, and eventual royalties. This customer base is already broad enough to segment meaningfully. There are product-license partners such as Ono and Janssen, platform-license partners such as SOTIO and Ono, co-development and rights-split relationships such as Iksuda plus Fosun, and partnered development relationships such as CStone and NextCure. The official history page shows these are not one-off names added for prestige; the partner list extends over many years and multiple asset types. The implication is that LigaChem has real BD-market adoption in the global ADC ecosystem. The unresolved question is not whether counterparties exist, but how concentrated their economics are.[CU001, CU002, CU003, CU004, CU005, CU006]
| Segment | Buyer / user / payer | Use case | Scale | Revenue / strategic value | Gap |
|---|---|---|---|---|---|
| Product-license pharma partner | Buyer: BD/R&D; User: clinical-development org; Payer: upfront/milestone counterparty | License a named ADC asset for global development | Anchor named accounts include Ono and Janssen | Can generate very large milestone pools plus royalties | No public renewal or satisfaction metrics |
| Platform-license oncology partner | Buyer: partner discovery/portfolio team; User: partner ADC teams; Payer: platform fees and milestones | Use ConjuAll and linker-payload stack against partner-selected targets | Named proof includes SOTIO and Ono | Validates the platform beyond a single molecule | Commercial depth per target remains opaque |
| Rights-split regional partner | Buyer: regional biotech/pharma; User: local clinical/commercial teams; Payer: licensee by territory | Develop the same asset under territorial rights splits | Fosun in Greater China; Iksuda ex-Greater China/Korea for LCB14 | Expands reach without full in-house globalization | Creates fragmented customer economics |
| Co-development / equity-linked partner | Buyer: partner management + investor; User: joint pipeline teams; Payer: mix of licensing and equity capital | Deepen relationship across multiple assets and control rights | Iksuda is the clearest example | Can capture more downstream value than a simple out-license | Raises governance and execution complexity |
| Clinical-collaboration partner | Buyer: partner R&D / translational teams; User: trial operators | Move a partnered asset through IND and Phase 1 activity | NextCure and CStone provide current proof | Creates external validation even before commercialization | Economics and timing can remain very lumpy |
End patients and trial sites are downstream users of partnered assets, but they are not the direct economic customers in LigaChem's present model.
[CU001, CU002, CU003, CU006, CU020]The customer journey is a long-cycle pharma-partner workflow, not a self-serve SaaS motion.
[CU002, CU006, CU012, CU023]6.2 Named Customer Proof: The Strongest Evidence Comes From Milestones and Trial Progress
The named proof set is much stronger than a normal startup logo page because several counterparties have already advanced into hard operational milestones. Ono is the cleanest example. The 2024 package deal covered both LCB97 and broader ConjuAll platform rights; by July 2026 the relationship had already progressed to first-patient dosing and a milestone estimated at more than 10% of prior-year revenue. SOTIO is another high-quality proof point: its 2021 agreement covered up to five programs, placed downstream development and commercialization responsibility with SOTIO, and by early 2026 had already yielded another milestone linked to SOT106 progress. Iksuda and CStone add multi-year continuity plus operating depth. Iksuda's relationship spans global rights to LCB14 outside Greater China and South Korea, later first-patient clinical activity, and eventually a strategic equity tie-up that pulls LigaChem closer to management participation. CStone advanced CS5001 from a 2020 license to Phase 1b by late 2024. Janssen and NextCure are also meaningful, though the retained public evidence here is thinner on fresh downstream milestones. Overall, the best rule is simple: a customer relationship becomes underwriteable only once it crosses from contract copy into trial registration, patient dosing, or milestone economics. LigaChem has several that do.[CU007, CU008, CU009, CU010, CU011, CU012]
| Customer | Segment | Deployment / use case | Production vs pilot | Outcome | Limitation |
|---|---|---|---|---|---|
| Ono Pharmaceutical | Product + platform partner | LCB97 global rights plus multi-target ConjuAll collaboration | Post-signing with first-patient dosing and milestone | Confirms progression from deal to clinical economics | Exact milestone amount undisclosed |
| SOTIO Biotech | Platform partner | Up to five ADC programs for solid tumors using LCB platform | Post-signing with milestone and pre-IND progress | Shows multi-program platform adoption and repeat monetization | Human efficacy proof still absent |
| Iksuda Therapeutics | Rights-split + equity-linked partner | Global ex-Greater China/Korea LCB14 / IKS014 and LCB73 pipeline expansion | Active Phase 1 programs and later equity deepening | Strongest land-and-expand example in retained set | Satisfaction and contract economics still opaque |
| CStone Pharmaceuticals | Product-license partner | CS5001 / LCB71 ROR1 ADC development outside Korea | Phase 1b clinical development | Shows multi-year durability from 2020 deal to later-stage human data | Revenue contribution to LigaChem undisclosed |
| Janssen / Johnson & Johnson | Big-pharma product partner | LCB84 Trop2 ADC development and commercialization rights | Phase 1/2 collaboration at signing stage | Validates LigaChem with a top-tier global pharma buyer | Fresh downstream milestone proof not retained here |
| NextCure | Clinical collaboration partner | LNCB74 B7-H4 ADC in Phase 1 | Clinical-development stage | Confirms an additional active partnered clinical program | Public economic terms not retained here |
In this business model, “production” means active clinical-development or milestone execution rather than consumer-scale commercial deployment.
[CU007, CU008, CU010, CU012, CU016, CU018]Public proof narrows from historical BD breadth into a smaller set of counterparties with fresh operational milestones.
This funnel measures evidence quality and maturity, not total customer count.
[CU005, CU021, CU022, CU026]Named customer evidence is not equally strong across the retained set.
[CU018, CU019, CU026, CU029, CU030, CU031]6.3 Durability, Expansion, and Concentration
Durability is the hardest part of the customer chapter because LigaChem is a biotech licensor, not a subscription software business. No retained source provides customer count by cohort, renewal rate, GRR, NRR, or even a partner revenue split. That forces the analysis onto proxies. The best available proxy is relationship continuity from initial deal to later milestones or deeper scope. By that standard the platform looks better than average. Iksuda has expanded from licensing into equity and pipeline control. Ono started with an asset-specific license but also bought into multi-target platform access. SOTIO moved from a platform agreement to later milestone proof. CStone advanced its licensed asset into later clinical stages. These are all signs of customers staying engaged after the initial press release. Still, durability is not the same as concentration transparency. Public proof is visibly clustered around a small number of counterparties and assets. Because economics in this model are lumpy and milestone-driven, one delayed study or one reprioritized partner can have an outsized effect on recognized revenue. The same 2026 financing that gives LigaChem more freedom to self-develop also underlines the gap: the company appears to be adding internal optionality precisely because partner-led monetization alone is not enough to smooth the revenue model. The customer base is strong on strategic quality, but it is not yet broad or transparent enough to dismiss concentration risk.[CU023, CU024, CU025, CU026, CU027, CU028]
| Metric | Value / null | Segment | Confidence | Diligence ask |
|---|---|---|---|---|
| Renewal rate | null | All partner segments | High | Request renewal and option-exercise history by counterparty |
| NRR / GRR | null | All partner segments | High | Request partner-level revenue cohorts and royalty flow-through |
| Multi-year continuity proxy | Present for selected anchor accounts | Ono, SOTIO, Iksuda, CStone | High | Map each partner from signing date to latest operational milestone |
| Customer satisfaction evidence | null | All partner segments | Medium | Request post-signing testimonials or diligence calls with counterparties |
| Repeat monetization evidence | Present but sparse | Ono and SOTIO specifically | Medium | Request milestone history by partner and asset |
| Churn / terminated relationships | null in retained set | All partner segments | Medium | Request terminated or inactive partnership history |
Durability today is proxied by continuity and milestones, not by reported cohort economics.
[CU026, CU027, CU028, CU031]| Expansion driver | Concentration risk | Impact | Diligence path |
|---|---|---|---|
| Package deals that combine a named asset with broader platform rights | A few strategic counterparties may dominate visible economics | One counterparty delay can materially change recognized revenue | Request partner-level revenue concentration and milestone calendar |
| Land-and-expand from license into equity or pipeline-control rights | Deeper ties can improve economics but raise governance dependence | Iksuda-style structures blur customer and affiliate boundaries | Review shareholder rights, governance, and transfer-pricing exposure |
| Regional rights splits for the same asset | Economics become fragmented across territories | Can complicate benchmarking of commercial success | Obtain asset-by-region waterfall for LCB14 / FS-1502 / IKS014 |
| Customer migration from pure licensing to self-development on core assets | May reduce future external deal flow if LigaChem keeps more rights | Could improve long-term value but compress near-term partnering surface | Clarify which assets remain open for partnership |
| Milestone-driven rather than recurring customer monetization | Short-term volatility and valuation sensitivity rise | Revenue visibility can fall sharply between milestone events | Map signed but untriggered milestones by customer and expected timing |
The customer chapter is strongest on named proof and weakest on concentration transparency.
[CU012, CU023, CU024, CU025, CU032, CU033]There is no public revenue-retention table, so the best available durability cohort is selected anchor-partner continuity rather than NRR.
This is a continuity cohort for selected named counterparties with explicit follow-on proof, not a revenue-retention cohort. It visualizes whether anchor partner relationships remained publicly active across later years.
[CU027, CU028]6.4 What This Means for Underwriting the Customer Base
The customer verdict is positive but qualified. LigaChem has clearly won adoption from sophisticated counterparties that understand ADC science and are willing to put real rights, money, and development resources behind those relationships. That is stronger evidence than generic startup references because the customers are themselves expert buyers. At the same time, the underwriting case depends on a narrow set of proof points: a handful of counterparties, milestone-based economics, and limited public visibility into satisfaction, concentration, and long-term royalty conversion. The practical implication is that investors should treat the customer chapter as validation of technology-market fit within global pharma, not as proof of smooth recurring revenue. The strongest diligence asks are partner-level revenue exposure, option and renewal behavior, and examples of failed or terminated relationships. If those are healthy, the named customer set becomes a real moat signal. If they are weak, the same small set of counterparties becomes a concentration vulnerability.[CU031, CU034, CU035, CU036, CU037]
| Metric | Value | Date | Source | Confidence | Implication | Missing denominator |
|---|---|---|---|---|---|---|
| Total out-licensing deals through 2024 | 15 | 2026 report citing through-2024 total | BigGo | Medium | Shows broad historical BD adoption | No split by active vs inactive deals |
| Cumulative disclosed technology-export value | KRW 9.6 trillion (~$6.3B) | 2026 | BigGo | Medium | Indicates high theoretical customer value capture | Not equivalent to realized cash receipts |
| Ono milestone threshold | >10% of 2025 revenue | 2026-07 | Sedaily | Medium | One customer event can be financially material | Exact amount undisclosed |
| SOTIO milestone progression | Milestone received / receivable | 2026-02 | LigaChem press release | Medium | Shows repeat monetization beyond signing | Amount undisclosed |
| Global clinical-trial proof across partner-led assets | At least 4 active human studies retained | 2026 | ClinicalTrials APIs | High | Customers are operating assets, not warehousing rights | No portfolio-wide active-study count officialized |
| Public revenue concentration split | null | 2026 | No retained disclosure | High | Major underwriting gap | Top-partner share unknown |
The public adoption story is strongest on headline BD count and named milestones, weakest on recurring economics and concentration visibility.
[CU005, CU009, CU011, CU015, CU022, CU026]07Risks
7.1 Top Risk Stack: More Capital, More Ambition, Still Clinical-Stage Fragility
LigaChem's central risk has not changed: it is still a company whose value depends on whether ADC molecules can cross the gap from mechanistic credibility into human efficacy, tolerability, and manufacturable reproducibility. What has changed is the scale of the ambition. The 2026 financing gives the company more runway to push late-stage development and even self-development, but that same shift also increases the number of ways the thesis can break. The company is no longer just a platform seller hoping for partner validation; it is becoming a hybrid platform-and-development company that may need to manage trial execution, capital allocation, CMC readiness, and partner relationships at the same time. That makes the risk stack multidimensional. Clinical failure remains the highest-severity risk because current studies are still early and none of the cited trials had posted results. Manufacturing and CMC are next because ADC performance depends heavily on conjugation quality and reproducibility, yet public quality evidence is thin. Partner and customer dependence remains high because several key assets sit under external control. Financing risk is lower than before the raise, but not removed, because the company is now funding a more expensive strategy. Finally, legal and IP protections look real but incomplete: active patents exist, yet public FTO visibility is limited.[CR001, CR002, CR003, CR007, CR008, CR018]
Clinical, CMC, and capital-allocation risks remain the highest-priority exposure areas.
[CR002, CR007, CR015, CR020, CR025, CR030]7.2 Regulatory, Legal, and Clinical Risk: The Science Is Real, the Proof Is Still Thin
The regulatory and clinical evidence simultaneously validates the platform and underlines the risk. Four active ClinicalTrials records show that multiple LigaChem-derived programs are genuinely in human testing, but all are still burdened by dose-escalation logic, biomarker gating, and exclusion criteria that are characteristic of drugs with uncertain therapeutic windows. LNCB74 excludes prior MMAE-ADC exposure and pulmonary or ocular risk factors; LCB02A excludes prior Topo1-payload ADC exposure; IKS014 excludes ILD and corneal abnormalities. These are not abstract concerns—they are built into the protocols. The absence of posted results means investors still do not know which programs can combine efficacy and tolerability at commercially relevant doses. The legal picture is better than a pure concept-stage platform but still incomplete. Google Patents records show active self-immolative and conjugation-related patents assigned to LigaChem, which is real protection. Yet public materials do not provide a complete FTO map, expiry matrix, or dispute history. The broader ADC field is demonstrably litigious, and even comparator conjugation families show litigation markers. The right conclusion is that IP is a mitigation, not a full answer. Without deeper diligence, legal/IP residual risk remains medium-to-high.[CR003, CR004, CR005, CR006, CR025, CR026]
| Rule / case / issue | Jurisdiction | Status | Likelihood | Severity | Mitigation | Residual exposure | Diligence path |
|---|---|---|---|---|---|---|---|
| Clinical efficacy or safety failure in early ADC studies | US / global | Active risk across Phase 1 and Phase 1/2 programs | High | Critical | Biomarker gating, dose escalation, exclusion criteria, partner validation | Still very high until posted human data matures | Track safety/efficacy readouts for LCB02A, LNCB74, IKS014, IKS03 |
| Regulatory delay in IND / trial progression for roadmap assets | US / Japan / global | Active risk for newer assets such as SOT106, LCB36, LCB58A | Medium-high | High | Existing partner network and 2026 capital raise | Timeline slippage can materially change valuation timing | Request updated regulatory calendars and gating assumptions |
| Freedom-to-operate / patent estate uncertainty | US / global | Partially mitigated by active patents, but incomplete publicly | Medium | High | Active patents assigned to LigaChem | Unknown FTO, expiry, and dispute scope | Obtain full patent landscape and outside-counsel FTO memo |
| ADC-related patent contention in adjacent fields | US / global | Visible comparator litigation marker exists | Medium | Medium-high | Build own estate and negotiate licenses where needed | Broader field may still force legal expense or design-arounds | Map competitor patent estates around conjugation and payload chemistry |
| Disclosure opacity on material events and contract terms | Korea / KOSDAQ | Publicly compliant but operationally thin | Medium | Medium | Routine voluntary disclosures and public filings | Investors still lack detail on counterparties, terms, and contingencies | Request fuller deal-term and milestone documentation |
The register ranks only the material legal/regulatory issues visible in public sources; it is not a substitute for counsel-led diligence.
[CR001, CR002, CR003, CR025, CR026, CR027]A few root risks can propagate through many parts of the company at once.
[CR011, CR015, CR020, CR023, CR034, CR041]7.3 Operational, Partner, and Customer Dependence Risk
LigaChem's partner model reduces some direct operating burden but creates another kind of fragility: value realization depends on many external organizations moving in sync. Ono controls LCB97 downstream. SOTIO controls research, development, manufacturing, and commercialization for its licensed programs. Iksuda runs key HER2 and CD19 programs while also sitting in a more entangled strategic relationship with LigaChem. CStone and NextCure operate additional externally advanced assets. The practical consequence is that LigaChem can show broad validation and still miss economic expectations if one or more partners slow enrollment, reprioritize pipelines, or fail to convert early data into later-stage investment. Customer concentration compounds that dependence. Public sources show strong named counterparties, but they do not show revenue splits, churn, or milestone timing by partner. The Ono milestone being worth at least 10% of prior-year revenue illustrates how concentrated the visible economics can be. Rights-split structures, such as the IKS014 / FS-1502 configuration across Iksuda and Fosun, add coordination and governance complexity. This is a diversified scientific ecosystem but probably not yet a diversified economic one.[CR011, CR012, CR013, CR014, CR015, CR016]
| Failure mode | Likelihood | Severity | Mitigation maturity | Residual exposure | Unresolved gap |
|---|---|---|---|---|---|
| CMC or batch reproducibility failure in ADC manufacturing | Medium-high | Critical | Low-medium | High | No public GMP or batch-release metrics retained |
| Payload / linker safety window too narrow for viable dosing | High | Critical | Medium | High | Current mitigations are protocol-level, not outcome-level |
| Global site recruitment and protocol execution slip | Medium-high | High | Medium | Medium-high | Several studies require large enrollment across multiple countries |
| Program-sprawl and management bandwidth overload | Medium | High | Medium | Medium-high | Many partnered and self-advanced assets compete for attention |
| Commercial-readiness gap if self-development advances too far | Medium | High | Low | High | No public launch, pharmacovigilance, or market-access infrastructure retained |
Operational risk is strongest where public evidence is missing: CMC, commercialization readiness, and scaled execution.
[CR007, CR009, CR010, CR024, CR039, CR040]| Dependency | Counterparty | Role | Concentration | Failure scenario | Severity | Mitigation | Residual exposure |
|---|---|---|---|---|---|---|---|
| LCB97 downstream development | Ono | Global development / manufacturing / commercialization | High | Trial slows, reprioritization, or weaker commercialization push | High | Deal already advanced to patient dosing and milestone receipt | High |
| Multi-target platform programs | SOTIO | Research to commercialization for licensed programs | Medium-high | Programs stall before IND or after preclinical signal | High | SOT106 milestone shows active continuation | Medium-high |
| HER2 / CD19 partner ecosystem | Iksuda and Fosun | Territorial rights, clinical development, strategic equity link | High | Coordination or capital misalignment across rights holders | High | Deeper strategic tie may improve control | High |
| ROR1 program external execution | CStone | Clinical development outside Korea | Medium | Later-stage investment does not follow early data | Medium-high | Phase 1b progress validates current commitment | Medium |
| B7-H4 program external execution | NextCure | Clinical development collaborator | Medium | Phase 1 signal disappoints or program is deprioritized | Medium-high | Current Phase 1 activity indicates live commitment | Medium |
The same partner set that validates the platform also limits LigaChem’s direct control over timing and value realization.
[CR011, CR012, CR013, CR014, CR015, CR016]LigaChem depends on a dense web of partners, regulators, capital providers, and internal specialists.
[CR011, CR012, CR013, CR023, CR031, CR034]7.4 Financial and Execution Risk: The Raise Buys Time, Not Certainty
Financial risk improved sharply in 2026 but remains central. Official 2025 statements show that LigaChem was not self-funding: operating loss exceeded KRW 100 billion, operating cash outflow exceeded KRW 120 billion, and year-end cash was under KRW 100 billion. The KRW 500 billion raise therefore mattered enormously. But the market should not confuse that with a solved business model. Independent reporting indicates the money is intended for late-stage trials, regulatory work, manufacturing, and commercialization readiness—the most expensive parts of drug development. The company may simply have upgraded itself into a higher-cost risk class. Execution risk follows from that. Governance shows meaningful Orion presence, which can help oversight but also raises strategic-control sensitivity. Leadership shows explicit attention to toxicology, safety, and manufacturing, which is a genuine mitigant. Recruiting materials show the company still depends on highly specialized scientific talent. The practical kill criteria are therefore straightforward: watch for safety setbacks, timeline slips in self-advanced assets, signs of faster-than-expected cash consumption, or any public indication that partner follow-through is weakening. If those indicators remain stable, the risk profile becomes more investable. If they break, the downside can re-rate quickly.[CR018, CR019, CR020, CR021, CR022, CR023]
| Role / function | Dependency or gap | Likelihood | Severity | Mitigation | Diligence path |
|---|---|---|---|---|---|
| Scientific leadership | Needs sustained excellence across chemistry, toxicology, and translational development | Medium | High | Named leadership and advisory coverage exists | Validate track records for late-stage ADC execution |
| CMC and manufacturing leadership | Critical if self-development deepens toward late-stage supply | Medium | High | Leadership page explicitly names ADC manufacturing/CMC expertise | Request CMC org chart and outsourced-manufacturing oversight model |
| Clinical program management | Multiple global studies and partner interfaces strain bandwidth | Medium-high | High | Partner network distributes some execution load | Request PMO structure and portfolio-prioritization process |
| Board oversight and sponsor alignment | Orion-linked board presence may accelerate or bias strategic decisions | Medium | Medium-high | Mixed inside/outside board composition | Review related-party governance safeguards |
| Talent pipeline | Recruiting process suggests dependence on PhD-level scientific talent | Medium | Medium-high | Active hiring process and specialized recruiting requirements | Assess retention, succession, and key-person exposure |
People risk is mitigated by visible expertise, but late-stage execution still requires more organizational proof than public sources provide.
[CR030, CR031, CR032]| Risk | Monitorable trigger | Threshold / event | Action implication |
|---|---|---|---|
| Clinical safety failure | Serious unexpected toxicity in LCB02A or LNCB74 | Dose-limiting pattern or study hold / major protocol tightening | Re-underwrite platform therapeutic-window claims |
| Capital sufficiency | Cash burn accelerates faster than milestone inflow | Evidence of another large raise before core readouts or commercialization clarity | Increase dilution and financing-risk haircut |
| Partner dependence | Named anchor partner deprioritizes or pauses a lead program | Loss of milestone cadence or removal from partner pipeline | Reduce assumed external-validation value and timing |
| CMC readiness | No disclosed progress on manufacturing or quality infrastructure as self-development deepens | Late-stage ambitions advance without new CMC evidence | Treat strategy shift as under-resourced |
| Execution sprawl | Roadmap assets slip materially versus 2026-2027 plans | Missed IND / Phase 1 start for LCB36 or LCB58A, or major slippage on LCB02A | Downgrade management-execution confidence |
The thesis is most fragile where multiple risks compound: safety, time, capital, and partner behavior.
[CR020, CR021, CR034, CR041, CR042]08Valuation
8.1 Investment Thesis and Anti-Thesis Must Start With Price Sensitivity
LigaChem is not a trivial company. It has a real ADC platform, meaningful partner validation, several active human programs, and enough financing to pursue a more ambitious strategy than many peers can afford. Those are genuine reasons the market grants it a premium. Big-pharma and specialist-biotech counterparties have repeatedly signed up to the platform, and the 2026 recapitalization plus continuing milestones show the company is more than a science project. The positive case, then, is clear: LigaChem has strategic value, product optionality, and enough market relevance to deserve continued investor attention. The anti-thesis is just as important. The current valuation already assumes a large share of that optionality will convert into future value. At roughly KRW 4.125 trillion of market cap and only about KRW 284 billion of 2026 revenue expectation, the market is not pricing a normal loss-making biotech on near-term fundamentals. It is pricing future pipeline and platform success. That can work if data and execution de-risk quickly. It becomes dangerous if investors mistake theoretical milestone ceilings, analyst target upside, or strategic sponsor validation for proved commercial economics. The first job of this chapter is therefore not to decide whether the company is good. It is to decide whether the current price is already doing too much of the future underwriting for the investor.[CV001, CV002, CV003, CV005, CV006, CV007]
| Argument | What would change the view |
|---|---|
| Real platform optionality with blue-chip partner validation | Would strengthen if current lead assets deliver human proof and CMC visibility |
| 2026 financing materially reduces immediate solvency risk | Would weaken if burn re-accelerates or another raise is needed before key inflections |
| Public market already prices substantial future success | Would improve if price compresses or evidence improves faster than the market expects |
| No marketed flagship product and no posted lead-trial results remain the core anti-thesis | Would weaken if proof-of-concept human data emerges in self-advanced assets |
The central debate is not company quality in the abstract; it is how much success is already embedded in the present quote.
[CV006, CV007, CV010, CV011, CV029, CV030]The current call flows from real strategic quality meeting a still-rich public entry price.
[CV010, CV011, CV029, CV030, CV033]IC-style summary of how the current evidence scores on the dimensions that matter most.
[CV009, CV010, CV011, CV030, CV032, CV033]8.2 Financing and Comparable Context Support a Premium, But Not an Unconditional One
Public comparables point in two different directions. On the one hand, listed development-stage ADC peers such as ADC Therapeutics and Sutro Biopharma trade at market values hundreds of millions of dollars below LigaChem. CStone, while a listed Asia oncology biotech with a broader commercial and clinical context, still screens below LigaChem on current market cap. This tells investors that the public market can be brutally skeptical even toward real ADC stories. On the other hand, strategic M&A anchors show what the top of the category can command: Seagen at roughly $43 billion and ImmunoGen at $31.26 per share after approved-product and late-stage validation. Those are enormous outcomes—but they were not paid for unproven stories. LigaChem sits between those two worlds. It is clearly stronger than a generic early platform company and arguably stronger than some public peers on partner validation and option value. But it is also meaningfully less de-risked than approved-product strategic takeouts. That is why a mixed comp set is the only honest approach. It also explains why the current public price feels rich rather than insane: the company deserves a premium, but not a premium so detached from proof that it stops being evidence-sensitive.[CV013, CV014, CV015, CV016, CV017, CV018]
| Comparable | Metric | Multiple / valuation / status | Relevance | Limitation |
|---|---|---|---|---|
| LigaChem current public quote | Market cap and forward sales | ~KRW 4.125T market cap; ~14.5x 2026 sales estimate | Best live entry anchor | Revenue base is still licensing-heavy and event-driven |
| ADC Therapeutics | Public market cap | ~$0.14-0.15B | Shows how cold public markets can be toward ADC stories | Different asset mix and commercial profile |
| Sutro Biopharma | Public market cap | ~$0.40-0.41B | Useful platform-oriented public comp | Still not a direct analogue for LigaChem’s partner model |
| CStone Pharmaceuticals | Asia-listed oncology biotech market cap | ~HKD 6.9B to 8.4B | Regional listed-biotech context closer to LigaChem than U.S.-only peers | Business model and product mix differ |
| Pfizer / Seagen acquisition | Strategic M&A EV | ~$43B enterprise value | Shows ceiling for a world-class approved ADC franchise | Far more de-risked than LigaChem |
| AbbVie / ImmunoGen acquisition | Strategic M&A and approved-product anchor | $31.26/share acquisition with approved ELAHERE and late-stage pipeline | Shows value uplift once product approval and label expansion are visible | Again, much later-stage than LigaChem |
This mixed comparable set is a feature, not a flaw: any cleaner comp set would be more precise-looking but less honest.
[CV001, CV003, CV013, CV014, CV015, CV016]A scenario range is more credible than a point estimate for the current proof stage.
Scenario ranges are evidence-sensitive, not DCF outputs. Base tops out around the current quote because much future success already appears reflected in price.
[CV001, CV003, CV023, CV033, CV034, CV035]8.3 Recommendation: Track / Research More Unless Price or Proof Improves
The right recommendation at the current quote is track / research more, not buy. This is not a dismissal of the company. It is recognition that the current valuation already assumes investors will receive a high-quality future evidence package: human data from the lead self-advanced assets, continued milestone conversions from partners, credible CMC readiness, and enough cash to reach those milestones without punitive dilution. That future package may arrive. But until it does, investors buying the stock aggressively are prepaying for a substantial amount of success. This is also why the call is price-sensitive. If the stock compresses materially without a corresponding deterioration of platform quality or financing position, the return case gets more attractive quickly. If the price rises further without human or CMC de-risking, the asymmetry worsens. The bull case is real; the base case is still slower and more conditional than the market seems to want; the bear case is easy to imagine because clinical, burn, and partner-dependence risks are all still alive. Medium confidence and high risk are therefore the disciplined output, not an evasive one.[CV027, CV028, CV029, CV030, CV031, CV032]
| Recommendation | Confidence | Risk rating | Valuation stance | Decision implication |
|---|---|---|---|---|
| Track / research more | Medium | High | Rich / proof-sensitive | Do not chase current price without better data or better entry |
| Conditional upgrade path | Medium improving to high | High falling to medium on proof | Would require stronger human, CMC, and economic evidence | Keep active diligence rather than passive watch only |
Recommendation is evidence-sensitive and price-sensitive, not a generic quality score.
[CV030, CV031, CV032, CV033]| Scenario | Assumptions | Valuation / return logic | Key risks | Probability signal |
|---|---|---|---|---|
| Bull | Early human traction in LCB02A, continued partner milestones, and credible CMC scale-up path | Supports value materially above current market cap and closer to strategic-premium logic | Still exposed to execution and dilution | Low-medium |
| Base | Platform remains valuable, but de-risking is slower and burn remains material | Current quote captures much of fair near-term value; upside requires patience | Proof, timing, and comp fit remain imperfect | Medium-high |
| Bear | Clinical delay, partner slippage, heavier burn, or multiple compression toward public peers | Value falls meaningfully below current quote and looks overextended in hindsight | Clinical and financing setbacks can compound quickly | Medium |
Scenario logic is milestone- and probability-sensitive because a single-multiple approach is too blunt for the current stage.
[CV034, CV035, CV036, CV039, CV042]A small number of unanswered questions dominate the plausible value range.
Ordinal impact bars; not a statistical model. They rank which diligence outcomes would move value most.
[CV034, CV036, CV039, CV040, CV042]8.4 Final Diligence Asks and Thesis-Break Triggers
The last step is to be explicit about what would change the view. An upgrade requires either better evidence or better price. Better evidence would mean: clear early human data in LCB02A or other priority assets, partner-level economics that show real cash-conversion quality, CMC evidence that supports eventual scale-up, and visibility into launch or late-stage readiness for self-developed assets. A better price would mean the market has given up some of the current optionality premium without the core thesis breaking. The main thesis-break triggers through 2027 are equally straightforward. If lead safety or efficacy signals disappoint, if the 2026 war chest burns down faster than expected, or if partner momentum stalls, the current premium can compress quickly toward public-peer territory. Conversely, if the company shows it can convert platform optionality into de-risked product value faster than it consumes capital, today’s premium will look more justified. Until then, the investment case remains live but not yet conviction-grade at the current price.[CV039, CV040, CV041, CV042]
| Trigger | Threshold | Transmission to thesis | Action implication |
|---|---|---|---|
| Lead-asset safety or efficacy disappointment | Clear negative signal in LCB02A or LNCB74 human data | Undermines premium platform narrative and self-development upside | Move stance toward avoid / underweight |
| Runway deterioration | Evidence the 2026 raise is insufficient before key inflections | Raises dilution risk and lowers strategic-option value | Demand lower entry price or stronger financing structure |
| Partner momentum stalls | Milestones slow, partner pipeline status weakens, or counterparties deprioritize assets | Weakens moat and customer-validation pillars | Cut probability of bull and base scenarios |
| CMC proof remains missing while self-development deepens | No visible manufacturing-readiness upgrade despite later-stage ambition | Makes premium harder to justify | Treat strategy shift as under-resourced |
| Price rises without proof | Quote moves materially above current level without de-risking evidence | Pushes asymmetry further against new investors | Remain on watchlist only |
The key kill criteria are mostly observable from public data and follow-on diligence, which makes the recommendation actionable.
[CV038, CV039, CV042]| Topic | Missing evidence | Why it matters | Owner or diligence path |
|---|---|---|---|
| Partner-level economics | Revenue splits, milestone calendar, royalty timing, counterparty exposure | Distinguishes real monetization quality from theoretical deal value | Finance + BD diligence with contract review |
| CMC and launch readiness | Manufacturing network, QA metrics, release history, launch planning | Determines whether self-development premium is credible | Operations + technical diligence |
| Freedom-to-operate and IP scope | Portfolio-wide patent family, expiry, license-in obligations, challenge history | Tests whether moat is defendable or merely plausible | IP counsel diligence |
| Analyst model assumptions | Probability-of-success, WACC, revenue ramp, and terminal logic behind targets | Prevents over-reliance on opaque public targets | Sell-side note collection and model rebuild |
| Capital path to key inflections | Cash use by asset and minimum financing needed to reach decisive readouts | Clarifies whether current premium should include future dilution | Management diligence and scenario model |
If these diligence asks close well, the recommendation can upgrade even without a dramatic change in the business itself.
[CV040, CV041, CV042]Disclaimer
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.
Evidence index
| ID | Statement | Confidence | Sources |
|---|---|---|---|
| CO001 | LigaChem Biosciences is a clinical-stage biopharmaceutical company focused on innovative medicines for diseases with high unmet medical need. | High | SO002, SO015 |
| CO002 | Founder-chairman Yong-Zu Kim says he founded LigaChem Biosciences in 2006. | High | SO005, SO015, SO016 |
| CO003 | The company headquarters are in Daejeon, South Korea at 10, Gukjegwahak 10-ro, Yuseong-gu. | High | SO006, SO015, SO016 |
| CO004 | LigaChem Biosciences is publicly listed on KOSDAQ under ticker 141080. | High | SO003, SO009, SO015, SO016 |
| CO005 | The official company history says LigaChem listed on KOSDAQ through an IPO in 2013. | Medium | SO003 |
| CO006 | Official overview materials say the company concentrates its R&D on ADC and immuno-oncology programs using a next-generation ADC platform that combines medicinal chemistry with biologics. | High | SO001, SO002 |
| CO007 | The public leadership pages and Yahoo profile identify Sejin Park as CEO and President. | High | SO004, SO015 |
| CO008 | Yong-Zu Kim remains chairman while Sejin Park appears to run day-to-day operations as CEO, preserving founder influence alongside delegated execution. | Medium | SO004, SO005, SO011 |
| CO009 | The company changed its name from LegoChem Biosciences to LigaChem Biosciences in March 2024. | High | SO003, SO015 |
| CO010 | PAN Orion became LigaChem's largest shareholder in 2024. | Medium | SO003, SO018 |
| CO011 | The governance page lists Orion-related executives In Chul Heo, Suhwon Tam, and Yong Su Kwon as internal directors or recent board appointees. | Medium | SO011 |
| CO012 | The same governance page shows two external directors and reports 96% board attendance with 13 meetings in the latest disclosed year. | Medium | SO011 |
| CO013 | On 2026-06-26 LigaChem announced a KRW 500 billion direct investment led by the National Growth Fund and related investors. | High | SO012, SO014, SO018, SO019, SO020, SO024, SO025 |
| CO014 | The 2026 financing consists of KRW 170 billion of convertible bonds and KRW 330 billion of convertible preferred shares with 10-year tenor. | High | SO012, SO013, SO018, SO019 |
| CO015 | Korea Development Bank's managed strategic-industry fund contributes KRW 250 billion while Pan Orion and another financial investor provide the remaining KRW 250 billion. | Medium | SO018, SO019 |
| CO016 | Media and company materials frame the deal as both the first direct National Growth Fund investment in a biotech company and the first direct investment by the fund into a listed company. | High | SO012, SO019, SO020, SO024 |
| CO017 | The investor Q&A says the issue price was determined by statutory capital-markets formulas and no discount was applied. | High | SO012, SO013 |
| CO018 | The same Q&A says conversion rights begin only after 24 months and one-year lockup or split restrictions apply to the issued securities. | High | SO012, SO013 |
| CO019 | Company materials say LigaChem already held roughly KRW 450 billion of cash before the new financing. | High | SO013, SO018 |
| CO020 | Seoul Economic Daily reported that the new money would take combined cash and cash equivalents into the KRW 900 billion range. | Medium | SO020 |
| CO021 | Management said the new capital is for R&D and late-stage clinical development rather than for M&A or control transactions. | High | SO012, SO013, SO019, SO020 |
| CO022 | Management said the financing adds an in-house late-stage development option without replacing the company's licensing-out strategy. | High | SO013, SO018, SO019 |
| CO023 | Vision 2030 still describes the business model through roughly 2027 as early-stage out-licensing combined with value inflection from advancing selected internal assets into phase 1/2. | Medium | SO007 |
| CO024 | The official history records a 2023 licensing partnership with J&J for the TROP2-targeted ADC LCB84. | Medium | SO003, SO022, SO023 |
| CO025 | BioSpace and Pharmaceutical Technology say the J&J/Janssen LCB84 deal is worth up to $1.7 billion, including a $100 million upfront payment and a $200 million option exercise fee. | Medium | SO022, SO023 |
| CO026 | The official history records a 2024 package deal with Ono Pharmaceutical for LCB97 and a multi-target ADC platform license. | Medium | SO003 |
| CO027 | The official history records a 2022 licensing partnership with Amgen for multi-target ADC research and development. | Medium | SO003 |
| CO028 | The official history records a 2022 co-development partnership with NextCure on a B7-H4 ADC. | Medium | SO003 |
| CO029 | The official history says LigaChem repeatedly won World ADC Awards recognition for its platform between 2021 and 2025. | Medium | SO003 |
| CO030 | The official history says LCB97/ONO-7429 received phase 1 IND approval in Japan in April 2026. | Medium | SO003 |
| CO031 | The official history says LCB02A received U.S. phase 1/2 IND approval in May 2026. | Medium | SO003 |
| CO032 | The official history says LNCB74 received U.S. phase 1 IND approval in December 2024. | Medium | SO003 |
| CO033 | Korea Biomedical Review reported that LigaChem had completed 14 global licensing deals, 11 of them in ADCs, by June 2026. | Medium | SO018 |
| CO034 | The same Korea Biomedical Review article said the company was running eight global clinical trials, including a phase 3 LCB14 study led by Fosun Pharma. | Medium | SO018 |
| CO035 | Public company pages disclose a Daejeon headquarters and a separate Seoul office for pharmaceutical sales. | High | SO006, SO016 |
| CO036 | On runDate 2026-08-07 the official stock page showed a KRW 113,200 share price with a 52-week high of KRW 225,000 and a 52-week low of KRW 76,900. | Medium | SO009 |
| CO037 | GlobalNewstop reported that LigaChem's shares fell 8.28% on the 2026-06-26 funding day and remained roughly half the 52-week high, indicating the raise did not trigger an immediate rerating. | Medium | SO021 |
| CO038 | The official disclosure page on 2026-08-07 still highlighted completed issuance results from 2026-07-24 and a 2026-07-09 LCB97 milestone-fee receipt. | Medium | SO010 |
| CO039 | LigaChem filed a Notice on Investor Relations with Korean DART on 2026-06-30, showing an active listed-company communication cadence after the June financing. | Medium | SO017 |
| CM001 | LigaChem's relevant market spans both downstream ADC therapeutics and the upstream platform-licensing market that sells ADC assets into larger pharma pipelines. | High | SM001, SM002, SM003, SM024 |
| CM002 | The core market should include approved ADC product sales, clinical-development spending, and licensing demand tied to oncology ADC assets rather than all oncology drug spend. | Medium | SM003, SM005, SM006 |
| CM003 | The core market should exclude conventional chemotherapy, unconjugated monoclonal antibodies, cell therapy, and generic biologics except where they act as substitutes or comparison sets. | Medium | SM004, SM012 |
| CM004 | Grand View Research estimated the global ADC market at USD 11.29 billion in 2023 and projected USD 24.01 billion by 2030. | Medium | SM004 |
| CM005 | The Business Research Company estimated the ADC market at USD 20.28 billion in 2026 and USD 46.95 billion by 2030. | Medium | SM005 |
| CM006 | Mordor Intelligence projected ADC market growth from USD 20.12 billion in 2026 to USD 71.55 billion by 2031. | Medium | SM007 |
| CM007 | Fairfield Market Research projected the ADC market at USD 16.80 billion in 2026 and USD 35.99 billion by 2033. | Medium | SM008 |
| CM008 | Research and Markets projected USD 13.77 billion of incremental ADC market growth during 2025-2030 at a 15.7% CAGR. | Medium | SM006 |
| CM009 | The spread between roughly USD 16.8 billion and USD 20.3 billion for 2026 shows that public ADC TAM estimates are methodology-sensitive and should be treated as a range, not a single canonical number. | Medium | SM005, SM006, SM007, SM008 |
| CM010 | Grand View defined ADCs as antibodies linked to cytotoxic drugs that aim to improve efficacy and reduce systemic toxicity relative to conventional chemotherapy. | Medium | SM004 |
| CM011 | The Business Research Company segments ADC end users into hospitals, clinics, and other care settings. | Medium | SM005 |
| CM012 | Mordor Intelligence said hospitals generated 51.55% of ADC revenue share in 2025. | Medium | SM007 |
| CM013 | Fairfield said breast cancer accounted for 40.0% of the ADC market in 2026. | Medium | SM008 |
| CM014 | Grand View said the breast-cancer segment dominated ADC revenue in 2023 with a 47.76% share. | Medium | SM004 |
| CM015 | Grand View said HER2-targeted ADCs held the largest target segment share in 2023. | Medium | SM004 |
| CM016 | Fairfield said Enhertu represented 28.0% of the ADC market in 2026 and remained the broadest-indication active ADC franchise. | Medium | SM008 |
| CM017 | Mordor said topoisomerase I inhibitor payloads accounted for 53.53% of 2025 ADC value and cleavable linkers 72.15%. | Medium | SM007 |
| CM018 | Grand View likewise said cleavable linkers held 72.43% of ADC technology share in 2023. | Medium | SM004 |
| CM019 | Research and Markets identified rising cancer incidence, precision-oncology shift, linker and payload advances, and specialized manufacturing investment as core growth drivers. | Medium | SM006 |
| CM020 | The Business Research Company said rising clinical-trial activity is a core growth driver for the ADC market. | Medium | SM005 |
| CM021 | Mordor said 431 active ADC studies and 83 phase 3 trials were visible by January 2026, illustrating the scale of the development engine behind the market. | Medium | SM007 |
| CM022 | Fairfield said repeated label expansion in HER2 and TROP2 indications is broadening the addressable patient pool and moving ADCs toward earlier treatment lines. | Medium | SM008 |
| CM023 | Experimental Hematology & Oncology's 2026 AACR review said next-generation ADCs are evolving toward dual-payload, multispecific, and immune-integrated platforms designed to overcome heterogeneity, resistance, and systemic toxicity. | Medium | SM011 |
| CM024 | ADC Review's 2026 coverage described bispecific and novel ADCs as a rapidly expanding solid-tumor development wave. | Medium | SM013, SM014 |
| CM025 | The 2025 Frontiers review said ADCs still face systemic toxicity, drug resistance, tumor heterogeneity, and complex manufacturing processes despite their targeting advantages. | Medium | SM012 |
| CM026 | FDA's clinical-pharmacology guidance for ADCs explicitly requires bioanalytical methods, dosing strategy, exposure-response work, QTc, immunogenicity, and DDI analysis, making development more complex than simpler biologics. | Medium | SM010 |
| CM027 | Fairfield said HPAPI-qualified ADC manufacturing sites are scarce, command roughly 30-40% cost premiums, and can impose 18-to-24-month lead times for new entrants. | Medium | SM008 |
| CM028 | Pfizer CentreOne emphasizes that ADC manufacturing requires cGMP facilities and frequent inspections by a wide set of global regulators, reinforcing the sector's manufacturing-compliance burden. | Medium | SM022 |
| CM029 | Grand View said high production and research costs create reimbursement pressure because ADCs are more expensive than conventional chemotherapy or plain monoclonal antibodies. | Medium | SM004 |
| CM030 | NICE's Enhertu decision said cost-effectiveness uncertainty and an unacceptable NHS price can block routine reimbursement even for clinically important ADCs. | Medium | SM017 |
| CM031 | NICE guidance TA992 states that commissioners and providers must fund recommended use, showing that public-payer budget ownership is central to downstream ADC adoption. | Medium | SM018 |
| CM032 | PADCEV Support Solutions says coverage and reimbursement vary by payer, patient, and setting of care and must be verified before treatment starts. | Medium | SM019 |
| CM033 | Grand View said North America accounted for 52.54% of ADC revenue in 2023. | Medium | SM004 |
| CM034 | Fairfield said North America generated USD 6.72 billion in 2026 while Asia Pacific was set to grow at an 11.7% CAGR. | Medium | SM008 |
| CM035 | Mordor said North America's leadership is reinforced by Medicare coverage of outpatient ADC infusions and concentrated manufacturing capacity. | Medium | SM007 |
| CM036 | Fairfield highlighted Japan, South Korea, and China as Asia-Pacific markets where oncology reimbursement frameworks are expanding to accommodate targeted therapies. | Medium | SM008 |
| CM037 | Roche's 2026 ASCO update said it was presenting data from nine approved and investigational medicines including bispecific antibodies and ADCs, indicating that large incumbents now treat ADCs as core oncology modalities. | Medium | SM016 |
| CM038 | Roche's pipeline and BMS' modality pages show ADCs and other targeted modalities are embedded in mainstream oncology-development strategy rather than treated as fringe experiments. | Medium | SM015, SM023 |
| CM039 | The Business Research Company said Pfizer's USD 43 billion Seagen acquisition was aimed at strengthening oncology leadership through next-generation ADCs. | Medium | SM005 |
| CM040 | For LigaChem specifically, the immediate buyer is usually a large pharma or biotech partner licensing an ADC asset, while the downstream user is the oncologist and the downstream payer is an insurer or national health system. | High | SM002, SM003, SM011, SM018, SM019 |
| CP001 | LigaChem presents itself as a clinical-stage biopharmaceutical company whose R&D focus is next-generation ADCs and related oncology modalities. | Medium | SP001 |
| CP002 | LigaChem publicly emphasizes joint research, co-development, and licensing with global partners rather than direct commercialization today. | Medium | SP002 |
| CP003 | LigaChem's most relevant competitor set therefore starts with approved ADC franchise owners and platform licensors rather than only same-country early-stage biotechs. | High | SP001, SP002, SP022, SP023 |
| CP004 | ENHERTU is the strongest public benchmark in ADC because official product pages show unusually broad label breadth across multiple HER2-defined tumor settings and BioMed Nexus calls it the best-selling ADC. | High | SP005, SP006, SP024 |
| CP005 | Official ENHERTU patient and HCP sites show the franchise already spans early breast cancer, metastatic breast cancer, HER2-low or ultralow breast cancer, HER2-mutant NSCLC, gastric cancer, and HER2-positive solid tumors. | High | SP005, SP006 |
| CP006 | Pfizer's scale and the Seagen acquisition leave it positioned as a top ADC incumbent rather than a legacy lymphoma-only player. | Medium | SP003, SP024 |
| CP007 | BioMed Nexus describes Pfizer's roughly $43 billion Seagen acquisition as the defining ADC deal because it transferred multiple approved ADCs and a deep pipeline into big pharma hands. | Medium | SP024 |
| CP008 | ADCETRIS remains clinically important because its official patient site says it is approved across eight lymphoma indications and backed by more than a decade of clinical data. | Medium | SP007 |
| CP009 | ADCETRIS' HCP site carries a boxed warning for progressive multifocal leukoencephalopathy and extensive hematologic, pulmonary, dermatologic, and gastrointestinal precautions. | Medium | SP008 |
| CP010 | TRODELVY is a broader commercial competitor than a pipeline-only peer because its patient and HCP support sites show marketed use, ordering data, and structured financial-assistance workflows. | High | SP009, SP010 |
| CP011 | The TRODELVY HCP support site states the product is supplied as a 180 mg single-dose vial and explicitly offers benefits investigation, prior-authorization support, and assistance for uninsured patients. | Medium | SP010 |
| CP012 | PADCEV competes not only through its label but through formal reimbursement infrastructure: Astellas support materials require payer verification and offer commercial copay assistance up to $25,000 annually. | High | SP011, SP012 |
| CP013 | Approved ADC incumbents therefore compete with LigaChem on a full-stack basis that includes label breadth, safety management, reimbursement navigation, and patient-support operations. | High | SP006, SP008, SP010, SP012 |
| CP014 | ADC Therapeutics describes itself as a commercial-stage global leader in ADCs and says its portfolio includes an FDA-approved anti-CD19 ADC. | High | SP013, SP014 |
| CP015 | ADC Therapeutics' competitive focus remains narrower than large-pharma incumbents because public materials center on ZYNLONTA and hematologic malignancies rather than a multi-tumor commercial platform of ENHERTU scale. | Medium | SP013, SP014, SP024 |
| CP016 | Sutro positions itself as a next-generation ADC platform company with single- and dual-payload capabilities aimed at expanding treatable tumor types and overcoming resistance. | Medium | SP015 |
| CP017 | Sutro's public positioning suggests it competes with LigaChem more on linker-payload and platform sophistication than on current commercial reach. | Medium | SP015, SP021 |
| CP018 | Day One completed the acquisition of Mersana in January 2026, after which Mersana ceased trading on Nasdaq and became a wholly owned subsidiary. | High | SP018, SP019 |
| CP019 | Day One bought Mersana for $25 per share in cash plus CVRs, which is adverse evidence that an independent ADC platform can lose standalone bargaining power before late-stage proof is established. | High | SP018, SP019 |
| CP020 | Stock Analysis described Mersana before the acquisition as a clinical-stage ADC developer with B7-H4-targeting Emi-Le in phase 1 and additional preclinical assets, showing that technically differentiated platforms still faced financing pressure. | Medium | SP019 |
| CP021 | Hanmi is a credible Korean adjacent challenger because Aju Press reported it showcased BH4601, a B7H3 x PD-L1 bispecific ADC, and several other next-generation oncology modalities at AACR 2026. | Medium | SP026 |
| CP022 | Grand View lists AstraZeneca, Takeda, Roche, ADC Therapeutics, and Seagen among key ADC players, while Research and Markets lists AbbVie, Astellas, AstraZeneca, Daiichi Sankyo, Gilead, Pfizer, Roche, and ADC Therapeutics among leading vendors. | Medium | SP022, SP023 |
| CP023 | ChemExpress counted 23 approved ADCs worldwide as of June 30, 2026 across more than ten targets and more than ten tumor types, confirming that the field is no longer a narrow niche. | Medium | SP025 |
| CP024 | ChemExpress identifies Adcetris as a CD30-targeted MMAE ADC with a cleavable valine-citrulline linker and DAR of 4, highlighting how incumbent products already anchor well-understood technical archetypes. | Medium | SP025 |
| CP025 | ChemExpress also argues China-originated programs are increasingly setting the pace in global ADC innovation, adding another source of future partner competition for LigaChem. | Medium | SP025 |
| CP026 | BioMed Nexus says big pharma increasingly views it as faster and safer to buy or partner for ADC assets than to build from scratch, which structurally favors proven commercial buyers over small platform sellers. | Medium | SP024 |
| CP027 | BioMed Nexus and Research and Markets both describe strategic licensing, acquisitions, and vendor crowding as core features of the ADC field, implying high pre-deal multi-homing among pharma buyers. | Medium | SP023, SP024 |
| CP028 | Once a platform partnership is selected, switching costs rise because conjugation chemistry know-how, asset-specific data, and manufacturing process work have to be transferred or rebuilt. | Medium | SP001, SP002, SP024 |
| CP029 | Before deal signature, however, switching costs remain modest because pharma companies can evaluate multiple external ADC platforms and China-originated assets in parallel. | Medium | SP023, SP024, SP025 |
| CP030 | LigaChem lacks public evidence of the downstream reimbursement and patient-support infrastructure visible on approved-franchise sites, reinforcing that its present competition is upstream licensing rather than direct oncology-channel sales. | High | SP002, SP006, SP010, SP012 |
| CP031 | The approved-ADC leaders still face material toxicity burdens: ENHERTU warns on interstitial lung disease and neutropenia, ADCETRIS on PML and systemic toxicities, TRODELVY on neutropenia and diarrhea, and PADCEV on skin, lung, and neuropathy risk. | High | SP006, SP008, SP009, SP011 |
| CP032 | Manufacturing remains a competitive constraint rather than a solved utility because BioMed Nexus says ADC production combines biologic antibody manufacturing, toxic payload handling, and precise linker conjugation in scarce specialized capacity. | Medium | SP024 |
| CP033 | LigaChem's moat claim is therefore more about conjugation quality, partnerability, and repeat licensing than about being alone in ADC science. | Medium | SP001, SP002, SP022 |
| CP034 | That moat is only partially validated in public evidence because approved-franchise incumbents already own the strongest proof on label breadth, safety management, and reimbursement execution. | High | SP005, SP006, SP008, SP010, SP012 |
| CP035 | AbbVie's acquisition of ImmunoGen and Pfizer's takeover of Seagen show that big pharma is willing to pay up for de-risked ADC assets or franchises, which raises the value of strong Ligachem data but also concentrates buyer power in a few global companies. | Medium | SP003, SP016, SP017, SP024 |
| CP036 | Public market profiles for ADCT and STRO show that even known ADC specialists remain small-cap style equities relative to the pharmaceutical incumbents they compete against, a warning signal on standalone platform economics. | Medium | SP003, SP014, SP015, SP020, SP021 |
| CP037 | LigaChem therefore compares best against independent ADC platforms on technology and partnering, but against ENHERTU-, ADCETRIS-, TRODELVY-, and PADCEV-backed incumbents on the standard of proof required to become a preferred licensing counterparty. | High | SP002, SP005, SP007, SP009, SP011, SP014, SP015 |
| CP038 | Because 23 ADCs are already approved across many targets, LigaChem cannot rely on modality novelty alone and must differentiate through target choice, linker-payload performance, deal economics, or regional execution speed. | Medium | SP023, SP024, SP025 |
| CI001 | Official 2025 consolidated statements show KRW 141.553 billion of revenue for LigaChem. | High | SI001, SI013 |
| CI002 | Official 2025 statements break that revenue into KRW 121.161 billion of licence fee income and KRW 20.392 billion of goods sales. | Medium | SI001 |
| CI003 | Licence fee income accounted for roughly 86% of reported 2025 revenue, making the top line heavily dependent on deal timing rather than recurring product demand. | Medium | SI001 |
| CI004 | The company profile still says LigaChem sells medical device and supplies, which is consistent with goods sales being real but secondary to licensing economics. | Medium | SI001, SI012 |
| CI005 | Official 2025 statements show operating expenses of KRW 248.039 billion, including KRW 216.908 billion of R&D expense and KRW 31.131 billion of selling and administrative expense. | Medium | SI001 |
| CI006 | Official 2025 statements show an operating loss of KRW 106.486 billion. | High | SI001, SI013 |
| CI007 | The same official statements imply R&D spending was about 153% of 2025 revenue, underscoring how capital-intensive late-stage development has become. | Medium | SI001 |
| CI008 | Yahoo Finance shows gross profit of roughly KRW 125.996 billion in 2025, implying that reported gross margin looks high because licence fees carry little classical cost of goods sold. | Medium | SI013 |
| CI009 | Operating cash flow was negative KRW 124.533 billion in 2025 on both official and Yahoo cash-flow views. | High | SI002, SI014 |
| CI010 | Official cash-flow data show year-end 2025 cash and cash equivalents of KRW 98.650 billion. | High | SI002, SI014, SI016 |
| CI011 | Without fresh financing, year-end 2025 cash of KRW 98.650 billion would have covered less than one year of the prior year's operating cash burn. | High | SI002, SI014 |
| CI012 | Yahoo's balance-sheet view shows 2025 total assets of KRW 701.815 billion, total liabilities of KRW 160.695 billion, and total equity of KRW 541.120 billion. | High | SI003, SI015 |
| CI013 | Yahoo also shows working capital of roughly KRW 460.350 billion and total debt of just KRW 12.644 billion, indicating a lightly levered balance sheet before the 2026 raise. | Medium | SI015 |
| CI014 | Official 2025 cash-flow data show a financing cash inflow of KRW 443.379 billion in 2024, meaning LigaChem had already relied on external capital before the 2026 fundraise. | High | SI002, SI014 |
| CI015 | Yahoo's summary page shows Q1 FY26 revenue of KRW 35.89 billion and quarterly earnings of negative KRW 37.33 billion. | Medium | SI011 |
| CI016 | Bizhankook likewise reports first-quarter 2026 revenue of KRW 35.9 billion with sizable quarterly losses, reinforcing that the business remained loss-making entering the 2026 raise. | Medium | SI019 |
| CI017 | The June 2026 recapitalization totaled KRW 500 billion and was structured as KRW 170 billion of convertible bonds plus KRW 330 billion of convertible preferred shares. | High | SI008, SI021 |
| CI018 | Official Q&A materials say no discount rate was applied to the 2026 CB/CPS financing. | Medium | SI008 |
| CI019 | WOWTALE says the CB and CPS both have 10-year maturity and conversion rights that become exercisable 24 months after issuance. | Medium | SI021 |
| CI020 | BigGo says the conversion price for both the CB and CPS was KRW 149,300 per share and that full conversion would create about 9.05% additional shares versus the pre-issue base. | Medium | SI022 |
| CI021 | BigGo and Bizhankook both say Pan Orion contributed KRW 125 billion to the 2026 financing, with state-backed or KDB-linked capital supplying KRW 250 billion of the total. | Medium | SI019, SI022 |
| CI022 | Official management comments and WOWTALE say proceeds are earmarked for R&D and late-stage clinical development rather than M&A. | High | SI008, SI009, SI021 |
| CI023 | The 2026 raise supports a strategic shift from pure out-licensing toward selective late-stage self-development and eventual commercialization of priority assets. | High | SI009, SI021, SI023 |
| CI024 | The Ono package deal disclosed in October 2024 is worth up to $700 million plus royalties, showing how LigaChem monetizes its science through long-duration licensing contracts rather than simple transfer fees. | Medium | SI010 |
| CI025 | Seoul Economic Daily reported that the July 2026 LCB97 milestone payment corresponded to more than 10% of 2025 consolidated revenue, implying a minimum value above KRW 14.1 billion. | Medium | SI020 |
| CI026 | The same Sedaily report says LigaChem issued an invoice the same day and expected payment within 45 days, and that already-received milestone payments are not refundable even if a program later fails. | Medium | SI020 |
| CI027 | Because milestones can produce large revenue spikes but arrive unpredictably, LigaChem's revenue quality is higher on gross margin than on repeatability. | Medium | SI001, SI010, SI020 |
| CI028 | Classic SaaS-style CAC, payback, and sales-efficiency metrics do not fit LigaChem because its main monetization unit is the licensing deal or milestone, not a recurring seat or subscription. | Medium | SI001, SI026 |
| CI029 | A better GTM proxy is deal conversion and milestone progression, but partner-level conversion rates and concentration are not publicly disclosed. | Medium | SI004, SI026 |
| CI030 | Public traction metrics that are actually available include 2025 revenue, 2025 licence fee income, 2025 goods sales, 2025 cash flow, end-2025 cash, and Q1 2026 revenue. | High | SI001, SI002, SI011 |
| CI031 | Public metrics that remain missing include partner-by-partner revenue concentration, per-asset R&D spend, realized royalty rates, monthly burn, and exact runway by program. | Medium | SI004, SI006, SI025 |
| CI032 | Bizhankook presents the clearest adverse framing: widening losses, rapidly declining cash assets, and the risk that Orion could be pulled into repeated support as LigaChem takes assets deeper into clinical development. | Medium | SI019 |
| CI033 | Public sources conflict sharply on current cash: Yahoo-based cash-flow views suggest end cash near KRW 60.7 billion for the latest period, while Sedaily cites KRW 418 billion at end-Q1 2026 and Bizhankook cites roughly KRW 450 billion including existing cash before the raise. | Medium | SI014, SI019, SI024 |
| CI034 | That conflict likely reflects differing definitions or cut dates, such as cash and equivalents versus broader liquid resources or pre- versus post-transaction framing, but it prevents a clean public runway model. | Medium | SI014, SI019, SI020, SI021 |
| CI035 | Even using the conservative 2025 burn rate, the KRW 500 billion raise materially extends runway from sub-12 months toward multiple years of gross funding capacity. | High | SI002, SI009, SI021 |
| CI036 | However, the same strategy that justifies the raise—more late-stage self-development and commercialization preparation—will likely push burn higher than the simple 2025 base rate. | Medium | SI009, SI019, SI023 |
| CI037 | Yahoo's summary page shows a KRW 4.125 trillion intraday market cap on 2026-08-07, far above current revenue, indicating that equity value is being driven by pipeline expectations rather than earnings power. | Medium | SI011 |
| CI038 | The same page shows an average analyst target around KRW 211,667 versus a market price of KRW 113,200, reinforcing that the stock trades on forward optionality and wide dispersion in expectations. | Medium | SI011 |
| CI039 | The financial verdict from public data is that LigaChem has a credible monetization engine in licensing but not yet a self-sustaining operating model; capital adequacy improved sharply in 2026, while underwriting confidence remains limited by missing program-level and partner-level disclosure. | Medium | SI001, SI002, SI021, SI025 |
| CE001 | LigaChem defines itself as a clinical-stage biopharmaceutical company focused on ADC and immuno-oncology medicines built from medicinal chemistry expertise. | Medium | SE001 |
| CE002 | Official pipeline materials say the company's ADC platform claims differentiation in four specific dimensions: site-specific conjugation, linker stability, efficient toxin release, and pharmacokinetic profile. | Medium | SE002 |
| CE003 | The product delivered to customers is not a single marketed therapy but a stack of ADC assets plus platform-licensing capability that can be paired with external antibodies and partner development engines. | High | SE001, SE004, SE010 |
| CE004 | Official ADC pipeline materials enumerate a broad portfolio including HER2-MMAF, ROR1-pPBD, TROP2-MMAE, CD19-pPBD, B7H4-MMAE, L1CAM, CLDN18.2-Topo1i, LRRC15-MMAE, and CD20xCD22-pPBD programs. | Medium | SE003, SE020 |
| CE005 | LCB02A is in a first-in-human Phase 1/2 study for CLDN18.2-positive advanced solid tumors with estimated enrollment of 191 subjects and an estimated start of August 2026. | Medium | SE011 |
| CE006 | The LCB02A trial describes the asset as a CLDN18.2-directed human monoclonal antibody linked to a topoisomerase I inhibiting payload. | Medium | SE011 |
| CE007 | LNCB74 is in a recruiting Phase 1 study for advanced solid tumors with dose-escalation and dose-expansion parts, estimated enrollment of 145, and 21-day IV dosing cycles. | Medium | SE012 |
| CE008 | The LNCB74 trial uses B7-H4 expression assessment by central-lab immunohistochemistry as a named biomarker-related secondary objective. | Medium | SE012 |
| CE009 | IKS014 / LCB14 is in a global recruiting Phase 1 study for HER2-positive and HER2-low solid tumors, including breast and gastric cohorts. | Medium | SE013 |
| CE010 | ClinicalTrials and the NCI Drug Dictionary both describe caxmotabart entudotin / IKS014 / LCB14 as a HER2-targeting ADC with an MMAF payload. | High | SE013, SE015 |
| CE011 | The NCI Drug Dictionary adds that caxmotabart entudotin is site-specifically conjugated through a tumor-selective beta-glucuronide linker. | Medium | SE015 |
| CE012 | LCB73 / IKS03 is in a recruiting Phase 1 trial in advanced B-cell non-Hodgkin lymphoma. | Medium | SE014 |
| CE013 | The IKS03 trial describes the payload class as a pyrrolobenzodiazepine pro-drug attached to a CD19-targeting antibody. | Medium | SE014 |
| CE014 | The company's architecture therefore spans multiple payload families—including MMAF, MMAE, pPBD, and Topo1 inhibitor—rather than one linker-payload recipe reused everywhere. | High | SE003, SE011, SE013, SE014 |
| CE015 | SOT106 is a LigaChem-platform-derived LRRC15 ADC for sarcomas and other LRRC15-positive malignancies, with global IND submission planned for the second half of 2026. | High | SE008, SE009 |
| CE016 | The SOT106 partnership also shows LigaChem often delegates research, development, manufacturing, and commercialization to partners after providing platform technology. | Medium | SE008 |
| CE017 | The Iksuda investment release shows LigaChem sometimes moves beyond arm's-length licensing by taking management stakes to accelerate development and commercialization of transferred assets. | Medium | SE010 |
| CE018 | The same Iksuda release says Caxmotabart Entudotin, LCB73, IKS04, and IKS012 sit inside an integrated transferred pipeline, reinforcing that the platform is modular and partner-portable. | Medium | SE010 |
| CE019 | NextCure's pipeline page independently confirms that LNCB74 is in Phase 1 clinical development and is positioned around improved tumor killing with reduced toxicity. | High | SE012, SE024 |
| CE020 | ClinicalTrials locations show that LCB02A, IKS014, and IKS03 are being deployed through international trial networks rather than a Korea-only development model. | High | SE011, SE013, SE014 |
| CE021 | The customer or partner workflow runs from target and antibody selection, through ConjuAll-enabled conjugation and preclinical validation, into biomarker-gated clinical trials and, frequently, partner-led commercialization. | High | SE002, SE004, SE008, SE011 |
| CE022 | Clinical-trial materials reveal an oncology operating workflow that depends on RECIST response assessment, ECOG status screening, organ-function thresholds, and repeated 21-day IV cycles for at least two lead assets. | High | SE011, SE012, SE013 |
| CE023 | LNCB74's trial excludes prior MMAE-ADC exposure, active or historical pneumonitis/ILD requiring steroids, significant neuropathy, and corneal disorders, showing that toxicity management is embedded in protocol design. | Medium | SE012 |
| CE024 | LCB02A's trial excludes prior exposure to ADCs with a Topo1 inhibitor payload, again showing class-specific safety gating at the product-design level. | Medium | SE011 |
| CE025 | IKS014's trial excludes ILD/pneumonitis and clinically significant corneal abnormalities, which are well-known practical risks for certain HER2 ADC regimens. | Medium | SE013 |
| CE026 | Clinical-trial records for the cited lead assets all indicate FDA-regulated drug studies and all state that no expanded access is available. | High | SE011, SE012, SE013, SE014 |
| CE027 | No results are posted yet for the cited LCB02A, LNCB74, IKS014, or IKS03 studies, so the public evidence base is still mostly about design, enrollment, and mechanistic rationale rather than efficacy outcomes. | High | SE011, SE012, SE013, SE014 |
| CE028 | The careers process page functions as a practitioner proxy because it requires research statements, thesis abstracts, and interview presentations, which is consistent with a scientist-heavy translational R&D organization. | Medium | SE006, SE007 |
| CE029 | Public product-tech evidence does not disclose manufacturing-site certifications, batch-yield metrics, CMC uptime, or released quality-system statistics for the ADC platform. | Medium | SE002, SE004, SE008 |
| CE030 | Frontiers in Oncology and the AACR 2026 review both emphasize that ADC development remains constrained by systemic toxicity, resistance, tumor heterogeneity, and complex manufacturing. | High | SE016, SE018 |
| CE031 | AACR 2026 reviews show the broader modality moving toward dual-payload, multi-payload, and bispecific or immune-integrated designs, which raises the bar for a company claiming next-generation ADC leadership. | High | SE016, SE017 |
| CE032 | BigGo's roadmap summary says LigaChem is prioritizing LCB02A, LCB36, and LCB58A for accelerated direct development while also securing additional next-generation ADC platforms. | Medium | SE020, SE023 |
| CE033 | Sedaily's June 2026 funding coverage similarly ties the new capital to LCB02A and other proprietary ADC assets entering later-stage or self-development pathways. | Medium | SE021 |
| CE034 | The platform breadth claim is strongest on target and payload variety, but the public depth claim is weaker because most lead programs are still early-phase and efficacy proof remains non-public or partner-authored. | High | SE003, SE011, SE012, SE013, SE014 |
| CE035 | The Iksuda release's claim that Caxmotabart Entudotin showed superior efficacy and safety versus Enhertu and Kadcyla in a Chinese partner trial should be treated as company-authored and not as independently verified head-to-head proof. | Medium | SE010 |
| CE036 | The public operating model is therefore hybrid: some assets remain pure partner licenses, while others are being pulled closer to LigaChem through direct development funding or strategic equity stakes. | High | SE008, SE010, SE020, SE021 |
| CE037 | Customer workflow at the patient level is biomarker-positive refractory oncology treatment, but customer workflow at the business level is pharma-partner access to conjugation know-how and de-risked pipeline options. | High | SE001, SE004, SE011, SE012 |
| CE038 | The core product-tech blockers are missing public manufacturing/quality proof, absent posted clinical results, and dependence on external partners for much of the downstream development and commercialization stack. | Medium | SE008, SE016, SE018, SE025 |
| CU001 | LigaChem's present paying customers are primarily pharma and biotech counterparties that license assets or platform rights, not hospitals or end consumers. | High | SU001, SU003, SU005, SU009 |
| CU002 | The practical buyer/user/payer split is partner BD and R&D teams as buyers, partner clinical and commercialization organizations as operators, and milestone or royalty obligations as the economic payment mechanism back to LigaChem. | High | SU001, SU005, SU008, SU009 |
| CU003 | LigaChem itself frames the partner model as joint research, co-development, and licensing with global partners. | Medium | SU001 |
| CU004 | The official history page shows repeated partner deal flow from at least Fosun in 2015 through J&J in 2023 and Ono in 2024, which is evidence of sustained business-development adoption rather than a one-off collaboration. | Medium | SU002 |
| CU005 | BigGo reports that LigaChem had signed a total of 15 out-licensing deals through 2024 with cumulative technology export value of about KRW 9.6 trillion by mid-2026. | Medium | SU017 |
| CU006 | The customer base can be segmented into product-license partners, platform-license partners, co-development partners, and rights-split regional partners. | High | SU001, SU002, SU006, SU012 |
| CU007 | Ono is both a product customer and a platform customer because the 2024 package deal covered LCB97 rights plus a separate multi-target ConjuAll-based collaboration. | Medium | SU007, SU009 |
| CU008 | Ono received exclusive worldwide rights to develop, manufacture, and commercialize LCB97 for solid tumors, with up to $700 million in upfront and milestone economics plus royalties. | Medium | SU009, SU019 |
| CU009 | The July 2026 Sedaily report shows the Ono relationship has progressed from contract signature into first-patient dosing and a milestone worth more than 10% of LigaChem's prior-year revenue. | Medium | SU019 |
| CU010 | SOTIO is a platform customer that licensed rights for up to five ADC programs and took responsibility for research, development, manufacturing, and commercialization. | Medium | SU008 |
| CU011 | LigaChem's February 2026 SOT106 milestone release confirms the SOTIO relationship remained active several years after signing and was still generating milestone economics. | Medium | SU005, SU008 |
| CU012 | Iksuda is one of the clearest land-and-expand accounts because the relationship spans platform licensing, asset-specific licensing, global clinical advancement, and later strategic equity participation by LigaChem. | Medium | SU006, SU012, SU023 |
| CU013 | The Iksuda-HER2 relationship is geographically split: Iksuda holds global rights to LCB14/IKS014 excluding Greater China and South Korea, while Fosun holds Greater China rights as FS-1502. | Medium | SU012, SU023 |
| CU014 | Iksuda's programs give LigaChem customer proof beyond one molecule because the relationship covers IKS014 / LCB14, IKS03 / LCB73, and additional platform-derived assets such as IKS04 and IKS012. | Medium | SU006, SU012 |
| CU015 | ClinicalTrials records independently confirm that IKS014 and IKS03 are active human studies, which means Iksuda is operating as a real clinical-development customer rather than just a signed logo. | High | SU015, SU016 |
| CU016 | CStone is another multi-year customer proof point: it licensed the ROR1 ADC in 2020 and had advanced CS5001 into global Phase 1b by December 2024. | Medium | SU024, SU025 |
| CU017 | CStone's official materials also show the asset is being developed outside Korea under exclusive global rights, reinforcing LigaChem's role as an originator that monetizes via regional or global out-licensing. | Medium | SU024 |
| CU018 | NextCure provides a more modest but still real co-development customer surface because its pipeline page confirms LNCB74 is in Phase 1 clinical development. | High | SU010, SU014 |
| CU019 | Janssen / Johnson & Johnson is a named big-pharma product customer for LCB84, with a deal value of up to $1.7 billion and a collaboration during the ongoing Phase 1/2 trial before Janssen assumes sole downstream responsibility. | Medium | SU011, SU002 |
| CU020 | The retained customer set is geographically diverse across Japan, China, the United Kingdom, continental Europe, and the United States, which reduces dependence on a single domestic BD channel. | High | SU002, SU009, SU012, SU024 |
| CU021 | Adoption proof is strongest when a relationship has crossed at least one hard boundary such as IND approval, first-patient dosing, milestone receipt, or clinical-trial enrollment. | High | SU005, SU015, SU019, SU024 |
| CU022 | Several named customer relationships have crossed those hard boundaries: Ono to first-patient milestone, SOTIO to milestone plus pre-IND progress, Iksuda to first-patient and Phase 1 activity, and CStone to Phase 1b expansion. | Medium | SU005, SU019, SU023, SU024 |
| CU023 | LigaChem's customer journey runs from target or platform fit, through licensing and rights allocation, into partner-led clinical execution and eventually milestone or royalty flows. | High | SU001, SU008, SU009, SU012 |
| CU024 | Many customers—notably Ono and SOTIO—control downstream development, manufacturing, and commercialization rights, which means LigaChem often gives up operational control after creating or transferring the asset. | Medium | SU008, SU009 |
| CU025 | That structure makes customer monetization inherently lumpy: economics are driven by deal signing, option exercise, first-patient dosing, regulatory milestones, and eventual royalties rather than monthly recurring usage. | Medium | SU005, SU009, SU019 |
| CU026 | There is no public disclosure in retained sources for customer count by cohort, renewal rate, GRR, NRR, or revenue concentration by named partner. | Medium | SU017, SU019, SU020, SU021 |
| CU027 | In lieu of SaaS-style retention metrics, the best public proxy for durability is multi-year continuity from initial deal to later trials, options, milestones, or expanded rights. | High | SU002, SU005, SU006, SU024 |
| CU028 | Iksuda, SOTIO, CStone, and Ono all show explicit multi-year continuity between original deal announcement and later operational proof, which supports a favorable durability proxy even though renewal metrics are absent. | Medium | SU005, SU006, SU009, SU024 |
| CU029 | The customer-quality hierarchy is strongest for Ono, Iksuda, SOTIO, and CStone because those relationships have both named official proof and later-stage operational proof. | Medium | SU005, SU009, SU023, SU024 |
| CU030 | NextCure and Janssen are still credible named accounts, but their public proof retained here is thinner on recent milestones than the Ono, Iksuda, SOTIO, or CStone relationships. | Medium | SU010, SU011 |
| CU031 | Public evidence does not provide meaningful partner-side satisfaction data or any disclosed dissatisfaction metrics; customer satisfaction must therefore be treated as unverified. | Medium | SU001, SU005, SU009 |
| CU032 | The 2026 financing narrative shows the company is trying to keep the licensing-out customer model while adding a self-development option for selected priority assets. | Medium | SU017, SU018, SU020 |
| CU033 | That shift does not erase the customer base; instead it changes LigaChem's posture from pure technology seller toward a hybrid that can choose between earlier monetization and deeper value capture. | Medium | SU006, SU017, SU020 |
| CU034 | Customer concentration risk is probably material because a handful of milestone-bearing partners appear to account for most publicly visible commercial proof and because the company does not disclose partner-level revenue splits. | Medium | SU019, SU021 |
| CU035 | The Bizhankook article reinforces the concentration and durability concern indirectly by stressing that larger self-development commitments can raise dependence on a limited set of counterparties and capital providers before broad royalty flows exist. | Medium | SU021 |
| CU036 | The strategic value of anchor customers is high because they validate both asset-specific programs and the broader ConjuAll platform in negotiations with future global pharma partners. | Medium | SU005, SU009, SU011 |
| CU037 | New-partner adoption friction is likely nontrivial because counterparties need rights negotiation, target selection, payload-linker fit, and a long clinical-development commitment before commercialization is visible. | High | SU001, SU008, SU012 |
| CR001 | The public disclosure page shows that LigaChem remains highly event-driven, with material management information and voluntary disclosures tied to financing events, milestones, and rights changes. | Medium | SR001 |
| CR002 | The lead ADC portfolio is still predominantly early-phase or pre-IND, so clinical failure remains the first-order risk for the equity story. | High | SR014, SR015, SR016, SR017, SR029 |
| CR003 | None of the cited ClinicalTrials studies for LCB02A, LNCB74, IKS014, or IKS03 had posted results in the retained evidence set. | High | SR014, SR015, SR016, SR017 |
| CR004 | LNCB74 excludes prior MMAE-ADC exposure, ILD/pneumonitis, neuropathy, and corneal disorders, which is concrete evidence that toxicity window remains a live development risk. | Medium | SR015 |
| CR005 | LCB02A excludes prior Topo1-payload ADC exposure, showing that payload-class toxicity and prior-treatment history are active regulatory design constraints. | Medium | SR014 |
| CR006 | IKS014 excludes ILD/pneumonitis and clinically significant corneal abnormalities, again reinforcing that payload-associated pulmonary and ocular risks matter in real-world development. | Medium | SR016 |
| CR007 | Frontiers summarizes the generic ADC risk stack as systemic toxicity, drug resistance, tumor heterogeneity, and complex manufacturing. | Medium | SR018 |
| CR008 | AACR 2026 reviews show the competitive bar is moving toward bispecific and multi-payload ADCs, creating technology-obsolescence risk for any platform that cannot keep pace. | High | SR019, SR020 |
| CR009 | ClinicalTrials entries show enrollment targets of 191 for LCB02A, 145 for LNCB74, 165 for IKS014, and 140 for IKS03, implying substantial recruitment and execution burden across several concurrent studies. | High | SR014, SR015, SR016, SR017 |
| CR010 | Because the company now appears to be juggling multiple internal and partnered programs at once, portfolio-sprawl risk is rising rather than falling. | Medium | SR004, SR009, SR011 |
| CR011 | The 2024 package deal with Ono transferred exclusive worldwide development, manufacturing, and commercialization rights for LCB97 while also granting broader platform access, which makes LigaChem dependent on a partner for downstream execution. | High | SR025, SR012 |
| CR012 | SOTIO similarly controls research, development, manufacturing, and commercialization for the licensed ADC products under its agreement, leaving LigaChem reliant on partner follow-through. | High | SR024, SR029 |
| CR013 | The Iksuda structure adds complexity because LigaChem is simultaneously a licensor, strategic investor, and potential controlling shareholder in a counterparty that runs key pipeline programs. | Medium | SR028, SR031 |
| CR014 | CStone and NextCure provide validation but also confirm that major parts of the platform outcome are mediated by external clinical operators rather than by LigaChem alone. | Medium | SR026, SR027, SR030 |
| CR015 | The customer and partner model diversifies scientific validation but concentrates economic timing, because milestone events are tied to a finite number of counterparties and assets. | Medium | SR012, SR029, SR032 |
| CR016 | Ono's July 2026 milestone appears to be worth at least 10% of 2025 consolidated revenue, which is strong validation but also evidence that a single customer event can be financially material. | Medium | SR012 |
| CR017 | No retained public source discloses partner-level revenue concentration, churn, renewal behavior, or royalty timing. | Medium | SR009, SR010, SR011, SR012 |
| CR018 | Official 2025 statements show KRW 141.6 billion of revenue but KRW 248.0 billion of operating expenses and KRW 106.5 billion of operating loss, confirming that the pre-2026 model was not self-funding. | Medium | SR007 |
| CR019 | Official 2025 cash-flow statements show KRW 124.5 billion of operating cash outflow and only KRW 98.7 billion of year-end cash, which implies substantial funding risk absent the 2026 recapitalization. | Medium | SR008 |
| CR020 | The 2026 KRW 500 billion raise materially reduces near-term runway risk, but independent coverage makes clear that the company intends to spend that capital on late-stage clinical development, regulatory approval, manufacturing, and commercialization. | Medium | SR009, SR011, SR013 |
| CR021 | That spending plan means the raise solves timing risk more than it solves structural capital-intensity risk. | Medium | SR009, SR011, SR013 |
| CR022 | BigGo reports roughly 9.05% fully diluted share issuance from the CB/CPS package, showing that financing relief came with meaningful dilution potential. | Medium | SR009 |
| CR023 | Bizhankook argues that late-stage self-development, rising outsourcing cost, and widened losses can reopen questions about future Orion support despite the 2026 raise. | Medium | SR010 |
| CR024 | The public shift toward self-development therefore increases total execution complexity: LigaChem is trying to retain the upside of deeper control without yet having a marketed-product operating history. | Medium | SR011, SR013, SR025 |
| CR025 | Google Patents records show active LigaChem-assigned patents covering self-immolative groups and related conjugates, which is a real mitigation against pure platform commoditization. | High | SR021, SR022 |
| CR026 | Those same sources do not provide a complete freedom-to-operate map, litigation history for LigaChem's own families, or a portfolio-wide expiry schedule, so legal/IP uncertainty remains material. | Medium | SR021, SR022, SR004 |
| CR027 | The broader ADC IP field can be contentious: the comparator site-specific conjugation patent family cited here is marked as having litigation, showing that relevant patent estates can become contested. | Medium | SR023 |
| CR028 | Official history pages mention ConjuAll patent registrations in the U.S. and Japan plus novel linker chemistry patents, but public disclosures stop well short of a diligence-grade IP landscape. | Medium | SR004, SR021, SR022 |
| CR029 | The disclosure page itself is thin and list-like, which helps compliance but does not meaningfully reduce information asymmetry about the details of material events. | Medium | SR001 |
| CR030 | The governance page shows Orion-linked directors on the board, which improves sponsor alignment but also increases related-party and strategic-control sensitivity. | Medium | SR002 |
| CR031 | The leadership page shows named senior coverage for ADC research, toxicology/safety, and manufacturing/CMC, which partially mitigates execution risk by indicating that these functions are explicitly recognized. | Medium | SR003 |
| CR032 | The careers process page suggests LigaChem depends on highly specialized scientific talent, which means scaling delays or turnover in translational chemistry and clinical-development functions could be costly. | Medium | SR005 |
| CR033 | Because the company still lacks a marketed product, commercial-execution risk remains largely untested even if the science continues to progress. | Medium | SR011, SR025 |
| CR034 | SOT106, LCB97, CS5001, IKS014, IKS03, and LNCB74 all provide proof of partner appetite, but they also create many external handoff points where timing can slip outside LigaChem's control. | Medium | SR024, SR025, SR027, SR028, SR029, SR030 |
| CR035 | The rights-split around LCB14 / IKS014 / FS-1502 introduces additional coordination risk because one asset family is being advanced by different counterparties across territories. | Medium | SR031, SR016, SR022 |
| CR036 | NextCure's public description of LNCB74 as designed to reduce toxicity is directionally positive, but it does not substitute for disclosed human outcome data, so downside risk remains only partially mitigated. | Medium | SR026, SR015 |
| CR037 | CStone's official Phase 1b progression for CS5001 shows that some partnered assets are advancing well, but it also highlights that value realization depends on external companies choosing to keep investing through later stages. | Medium | SR027, SR030 |
| CR038 | The 2026 disclosure headline referencing sole-development rights and technology-transfer rights for LNCB74 shows that counterparty and rights architecture can still change materially, which is both optionality and governance risk. | Medium | SR001 |
| CR039 | No retained public source discloses named GMP certifications, batch-failure rates, release metrics, or recurrent supply-quality indicators for the ADC platform. | Medium | SR003, SR018 |
| CR040 | ADC reviews and protocol constraints together imply that even successful trial progression would leave residual exposure to manufacturing complexity, safety window management, and competitive benchmark risk. | High | SR014, SR015, SR018, SR019 |
| CR041 | The cleanest thesis-break triggers through 2027 would be: a major safety setback in LCB02A or LNCB74, a delayed IND or Phase 1 start for roadmap assets like LCB36/LCB58A, or evidence that the 2026 war chest is being consumed faster than milestones refill it. | Medium | SR009, SR010, SR011, SR014, SR015 |
| CR042 | The main diligence asks are therefore partner-level economics, full IP/FTO mapping, CMC quality evidence, and updated trial readouts; without those, residual risk stays high even if the narrative remains strong. | Medium | SR017, SR018, SR021, SR022 |
| CV001 | Yahoo Finance places LigaChem at a share price of KRW 113,200 and an intraday market cap of roughly KRW 4.125 trillion on 2026-08-07. | Medium | SV004 |
| CV002 | Yahoo analyst data shows current-year 2026 sales estimates of roughly KRW 284 billion and 2027 estimates of roughly KRW 286.48 billion. | Medium | SV005 |
| CV003 | At the current market cap, LigaChem is trading at roughly 14.5x 2026 estimated sales and about 14.4x 2027 estimated sales. | Medium | SV004, SV005 |
| CV004 | Yahoo shows a one-year analyst target estimate of roughly KRW 211,667 with a high target around KRW 230,000, implying visible modeled upside from the current quote. | Medium | SV004 |
| CV005 | That analyst-upside signal should be treated cautiously because the coverage base is thin and the business remains event-driven and clinical-stage. | Medium | SV004, SV005, SV001 |
| CV006 | Official financial statements confirm that 2025 revenue was KRW 141.6 billion and operating cash outflow was KRW 124.5 billion, so the equity story is still pricing future optionality rather than mature cash generation. | High | SV002, SV003 |
| CV007 | The 2026 KRW 500 billion raise materially improved runway and helps support a premium versus weaker cash-strapped clinical biotechs. | Medium | SV006, SV007, SV009 |
| CV008 | The same raise also confirms that LigaChem is moving into a more capital-intensive phase, which means part of the premium is being spent to buy strategic optionality rather than current earnings power. | Medium | SV007, SV008, SV009 |
| CV009 | BigGo reports that LigaChem had signed 15 out-licensing deals through 2024 with cumulative technology-export value of about KRW 9.6 trillion, which supports the argument for strategic platform value. | Medium | SV006 |
| CV010 | Ono, SOTIO, Janssen, Iksuda, NextCure, and CStone together provide a stronger customer-validation surface than most clinical-stage biotech peers enjoy. | High | SV010, SV011, SV013, SV029, SV030 |
| CV011 | However, there is still no marketed flagship LigaChem-owned product and no posted results for the current lead-trial set cited in this report. | High | SV014, SV015, SV016, SV017 |
| CV012 | That combination—real partner validation but incomplete human proof—means the company should be valued more as an option-rich platform than as a de-risked commercial oncology franchise. | High | SV006, SV010, SV014, SV015 |
| CV013 | ADC Therapeutics currently trades at about $146 million market cap on Yahoo Finance and about $140 million on CompaniesMarketCap, despite being a public ADC company with commercial exposure. | Medium | SV022, SV023 |
| CV014 | Sutro Biopharma currently trades at about $408 million market cap on Yahoo Finance and about $400 million on CompaniesMarketCap. | Medium | SV024, SV025 |
| CV015 | CStone Pharmaceuticals shows a market cap of about HKD 6.89-8.38 billion on Yahoo Finance, which is roughly sub-$1 billion USD and still well below LigaChem’s current public value. | High | SV026, SV013 |
| CV016 | These public-biotech comparables imply that LigaChem currently trades at a substantial premium to listed ADC or oncology-development peers on absolute market cap. | Medium | SV004, SV022, SV023, SV024, SV025, SV026 |
| CV017 | The premium is not irrational: LigaChem has broader platform optionality, meaningful licensing economics, and stronger strategic validation than many small public peers. | Medium | SV006, SV010, SV011, SV029, SV030 |
| CV018 | But the premium is still difficult to defend fully when current-trial proof is early and product revenue is not yet established. | High | SV002, SV014, SV015, SV016, SV017 |
| CV019 | Pfizer paid about $43 billion enterprise value for Seagen, a world-leading ADC franchise with approved products, scale, and deep pipeline breadth. | High | SV027, SV018 |
| CV020 | AbbVie paid $31.26 per share for ImmunoGen after ELAHERE approval, with the press release emphasizing approved-product status, label-expansion potential, and late-stage ADC pipeline value. | High | SV028, SV018 |
| CV021 | Those strategic M&A anchors show how much value the market can ascribe to differentiated ADC assets once product approval and commercialization are visible. | High | SV019, SV020 |
| CV022 | LigaChem is not yet close enough to those de-risked strategic precedents to justify being valued on the same logic today. | High | SV004, SV027, SV028 |
| CV023 | The company therefore sits awkwardly between two comp families: richer than current public clinical-stage ADC peers, but materially less de-risked than approved-product strategic takeouts. | High | SV016, SV019, SV022, SV024, SV027, SV028 |
| CV024 | A mixed comparable framework—public peers, strategic M&A, and deal-level licensing references—is more defensible than a single-multiple approach. | High | SV006, SV023, SV025, SV027, SV028, SV030 |
| CV025 | The Ono package deal, SOTIO multi-target agreement, and Janssen LCB84 deal all show that asset-level or program-level value creation can be large even before commercialization. | High | SV010, SV011, SV030 |
| CV026 | However, theoretical milestone ceilings cannot be capitalized at par because they depend on development success, counterparty persistence, timing, and downstream approvals. | Medium | SV010, SV011, SV030, SV008 |
| CV027 | Current public filings and disclosures show that LNCB74 and LCB97-related events are still material enough to move the information surface, which reinforces the event-driven nature of the stock. | High | SV001, SV004 |
| CV028 | The core thesis is that LigaChem owns real ADC option value across several assets and partnerships. | High | SV006, SV010, SV011, SV020, SV021 |
| CV029 | The core anti-thesis is that much of that option value is already reflected in the public market cap before current human-readout and CMC questions are answered. | High | SV003, SV004, SV005, SV011, SV018 |
| CV030 | At today’s quote, the correct recommendation is not buy but track / research more. | High | SV003, SV004, SV005, SV008, SV018 |
| CV031 | Confidence should be medium because valuation support exists, but comp fit and core proof remain imperfect. | Medium | SV004, SV005, SV023, SV027, SV028 |
| CV032 | Risk rating should remain high because the company is still clinical-stage, burn-heavy, and dependent on partner execution plus future data. | High | SV003, SV008, SV014, SV015 |
| CV033 | Valuation stance is rich but not absurd: the company deserves a premium to weaker ADC peers, yet current pricing still requires either more proof or better entry discipline. | High | SV004, SV006, SV022, SV024, SV028 |
| CV034 | The bull case requires at least three things to go right at once: strong early human data in self-advanced assets, continued partner milestone conversion, and evidence that self-development expands value faster than it increases burn. | Medium | SV006, SV007, SV010, SV014, SV015 |
| CV035 | The base case assumes the platform stays strategically relevant and financially viable, but that value accrues more slowly than the current premium might imply. | Medium | SV003, SV006, SV010, SV011, SV018 |
| CV036 | The bear case combines clinical delay, heavier-than-expected burn, partner slippage, and multiple compression toward public-peer territory. | Medium | SV003, SV008, SV022, SV024 |
| CV037 | A price compression toward roughly KRW 2.0-2.5 trillion equivalent, if unaccompanied by thesis damage, would make the entry case materially more interesting for new capital. | Medium | SV004, SV022, SV024 |
| CV038 | Conversely, a higher price without human-readout or CMC de-risking would worsen the risk/reward balance. | Medium | SV004, SV014, SV015, SV018 |
| CV039 | The most valuation-sensitive unknowns are LCB02A human data, partner milestone cadence, future dilution needs, and CMC proof. | High | SV003, SV006, SV014, SV015, SV020 |
| CV040 | Final diligence should focus on partner-level economics, runway to key readouts, CMC readiness, and freedom-to-operate, because those four areas would move both scenario probabilities and comp selection. | High | SV003, SV020, SV021, SV030 |
| CV041 | Exit-readiness is only medium-low today: the company is already public, but there is no visible approved-product or M&A process that would justify using a near-term exit multiple as a primary anchor. | Medium | SV004, SV027, SV028 |
| CV042 | The most important thesis-break triggers through 2027 are: safety or efficacy disappointment in lead assets, evidence the 2026 cash war chest is insufficient, or partner momentum slowing rather than compounding. | Medium | SV003, SV008, SV014, SV015 |
| ID | Publisher | Title | Quote |
|---|---|---|---|
| SO001 | LigaChem Biosciences | LigaChem Biosciences homepage | |
| SO002 | LigaChem Biosciences | About Us - Overview | LCB is a clinical stage biopharmaceutical company dedicated to the discovery and development of innovative medicines. |
| SO003 | LigaChem Biosciences | History | |
| SO004 | LigaChem Biosciences | Leadership | |
| SO005 | LigaChem Biosciences | Message from Chairman | Since founding LigaChem Biosciences in 2006, I have been striving my utmost to realize the lifelong mission to this day. |
| SO006 | LigaChem Biosciences | Location | |
| SO007 | LigaChem Biosciences | VISION 2030 | |
| SO008 | LigaChem Biosciences | Partnerships | |
| SO009 | LigaChem Biosciences | Stock | |
| SO010 | LigaChem Biosciences | Disclosure | |
| SO011 | LigaChem Biosciences | Governance | |
| SO012 | LigaChem Biosciences | Shareholder notice on National Growth Fund direct investment | The company has attracted direct equity investment of 500 billion won from the National Growth Fund. |
| SO013 | LigaChem Biosciences | Investor Q&A on National Growth Fund direct investment | This funding consists of 170 billion won in CB and 330 billion won in CPS, and no discount rate was applied. |
| SO014 | LigaChem Biosciences | Press release to shareholders on National Growth Fund direct investment | |
| SO015 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Company Profile & Facts | |
| SO016 | Stock Analysis / S&P Global Market Intelligence | LigaChem Biosciences (KOSDAQ:141080) Company Profile & Description | |
| SO017 | Financial Supervisory Service DART | LigaChem Biosciences / Notice on Investor Relations / 2026.06.30 | |
| SO018 | Korea Biomedical Review | Korea's chip fund makes first biotech bet, backing LigaChem with $323 million | |
| SO019 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund in First Direct Investment in Biotech Sector | |
| SO020 | The Korea Economic Daily / Seoul Economic Daily English | LigaChem Bio Secures 500 Billion Won Direct Investment from State Fund | |
| SO021 | NEWSTOP | LigaChem Biosciences Secures $323.6 Million From National Growth Fund | However, this favorable mood is not directly affecting the share prices of listed biotech companies in today's trading. |
| SO022 | BioSpace | LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC | LCB is eligible for up to potentially USD 1.7 billion in total consideration including an upfront payment of USD 100 million and an option exercise payment of USD 200 million. |
| SO023 | Pharmaceutical Technology | J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem | |
| SO024 | CHOSUNBIZ | Public Growth Fund backs LigaChem and approves LIG D&A investment in Korea | |
| SO025 | thebell | 리가켐바이오, 국민성장펀드 "5000억 유치" 신약사 첫 사례 | |
| SM001 | LigaChem Biosciences | About Us - Overview | LCB is focusing its R&D capabilities on the ADC and Immuno-Oncology drugs using next generation ADC platform. |
| SM002 | LigaChem Biosciences | Partnerships | |
| SM003 | LigaChem Biosciences | VISION 2030 | |
| SM004 | Grand View Research | Antibody Drug Conjugates Market Size | Industry Report 2030 | The global antibody drug conjugates market size was estimated at USD 11.29 billion in 2023 and is expected to reach USD 24.01 billion by 2030. |
| SM005 | The Business Research Company | Antibody Drug Conjugates Market Size, Drivers Report 2026-2030 | The antibody drug conjugates market size will grow from $16.53 billion in 2025 to $20.28 billion in 2026. |
| SM006 | Research and Markets | Antibody Drug Conjugates Market 2026-2030 | The global antibody drug conjugates market is forecasted to grow by USD 13.77 billion during 2025-2030, accelerating at a CAGR of 15.7%. |
| SM007 | Mordor Intelligence | Antibody Drug Conjugates Market Size, Share & Industry Growth Report 2031 | The Antibody Drug Conjugates Market size is expected to grow from USD 15.61 billion in 2025 to USD 20.12 billion in 2026 and is forecast to reach USD 71.55 billion by 2031. |
| SM008 | Fairfield Market Research | Antibody Drug Conjugate Market Size, Growth and Outlook 2033 | The global antibody drug conjugate market is expected to be valued at US$ 16.80 Billion in 2026 and is projected to reach US$ 35.99 Billion by 2033. |
| SM009 | U.S. Food and Drug Administration | Novel Drug Approvals for 2026 | |
| SM010 | U.S. Food and Drug Administration | Clinical Pharmacology Considerations for Antibody-Drug Conjugates Guidance for Industry | |
| SM011 | Experimental Hematology & Oncology / Springer | Advances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meeting | |
| SM012 | Frontiers in Oncology | Antibody–drug conjugate: a newly developed biological missile for tumor treatment | |
| SM013 | ADC Review | AACR 2026: Emerging Antibody-Drug Conjugates for the Treatment of Solid Tumors (Part 1) | |
| SM014 | ADC Review | Advances in Bispecific and Novel Antibody-Drug Conjugates: Highlights from AACR 2026 | |
| SM015 | Roche | Product Development Pipeline | |
| SM016 | Roche | Roche to present new data at ASCO 2026 | |
| SM017 | NICE | NICE publishes final draft guidance on Enhertu after commercial discussions conclude | Without a commercial arrangement that results in a price that represents a cost-effective use of NHS resources, NICE cannot recommend Enhertu. |
| SM018 | NICE | Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy | |
| SM019 | Astellas Pharma Support Solutions | PADCEV Support Solutions for Healthcare Providers | |
| SM020 | NICE | Technology appraisal data: cancer appraisal recommendations | |
| SM021 | NICE | Economic evaluation | NICE technology appraisal manual | |
| SM022 | Pfizer CentreOne | ADC Services | Antibody Drug Conjugates | |
| SM023 | Bristol Myers Squibb | Science in action | |
| SM024 | LigaChem Biosciences | History | |
| SM025 | ICER | Policy Papers | Explore Our Research | |
| SP001 | LigaChem Biosciences | About Us - Overview | LCB is focusing its R&D capabilities on the ADC and Immuno-Oncology drugs using next generation ADC platform. |
| SP002 | LigaChem Biosciences | Partnerships | |
| SP003 | Pfizer | Investor Relations Overview | |
| SP004 | Daiichi Sankyo | Shareholders & Investors | |
| SP005 | ENHERTU | Official Patient Website | ENHERTU is a prescription medicine used to treat adults with ... HER2-positive ... HER2-low ... HER2-ultralow ... NSCLC ... gastric cancer ... solid tumors. |
| SP006 | ENHERTU | Official HCP Site | ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for ... HER2-Positive Early Breast Cancer ... HER2-Positive Metastatic Breast Cancer ... HER2-Low and HER2-Ultralow ... NSCLC ... Gastric Cancer ... Solid Tumors. |
| SP007 | ADCETRIS | Official Patient Website | ADCETRIS is FDA approved to treat certain types of lymphoma across 8 different indications. |
| SP008 | ADCETRIS | Official HCP Website | JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients. |
| SP009 | TRODELVY | Official Patient Website | TRODELVY can cause serious side effects, including low white blood cell count and diarrhea. |
| SP010 | TRODELVY | Financial Assistance & Cost Support for HCPs | TRODELVY (180 mg) for injection is supplied as a sterile ... single-dose vial. |
| SP011 | PADCEV | Official Patient Site | PADCEV may cause serious side effects, including: Skin reactions ... Lung problems ... Nerve problems. |
| SP012 | Astellas Pharma Support Solutions | PADCEV Support Solutions for Healthcare Providers | The Program has an annual maximum copay assistance limit of $25,000 per calendar year. |
| SP013 | ADC Therapeutics | Corporate Website | Our technology includes an FDA-approved anti-CD19 ADC. |
| SP014 | ADC Therapeutics | Investors | Overview | ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). |
| SP015 | Sutro Biopharma | Investors | At Sutro, we are advancing a cutting-edge, next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs. |
| SP016 | AbbVie | Investor Overview | |
| SP017 | AbbVie | AbbVie Completes Acquisition of ImmunoGen | |
| SP018 | Day One Biopharmaceuticals | Day One Completes Acquisition of Mersana Therapeutics | Mersana became a direct wholly owned subsidiary of Day One. |
| SP019 | Stock Analysis | Mersana Therapeutics (MRSN) Company Profile & Description | Jan 6, 2026 - MRSN was delisted (reason: acquired by DAWN). |
| SP020 | Yahoo Finance | ADC Therapeutics SA (ADCT) Company Profile & Facts | |
| SP021 | Yahoo Finance | Sutro Biopharma, Inc. (STRO) Company Profile & Facts | |
| SP022 | Grand View Research | Antibody Drug Conjugates Market Size | Industry Report 2030 | Key players, such as AstraZeneca, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., ADC Therapeutics, Seagen, Inc., and others, are collaborating to develop & commercialize these products. |
| SP023 | Research and Markets | Antibody Drug Conjugates Market 2026-2030 | The report provides a detailed analysis of several leading global antibody drug conjugates market vendors. |
| SP024 | BioMed Nexus | ADCs in 2026: The Deals, the Data and the Players | Enhertu ... has become the best-selling ADC ... Pfizer’s acquisition of Seagen, valued at roughly $43 billion, was the defining ADC deal. |
| SP025 | ChemExpress | Global ADC Landscape 2026H1 | As of June 30, 2026, 23 antibody-drug conjugates (ADCs) have received regulatory approval worldwide. |
| SP026 | Aju Press | Hanmi Pharmaceutical Unveils Next-Generation Cancer Drug Pipeline at AACR 2026 | Hanmi said BH4601 is a bispecific antibody-drug conjugate that targets B7H3 and PD-L1 at the same time. |
| SI001 | LigaChem Biosciences | Financial Information - Consolidated Financial Statements (income statement view) | Revenue 141,553 ... Licence fee income 121,161 ... Operating profit -106,486. |
| SI002 | LigaChem Biosciences | Financial Information - Consolidated Financial Statements (cash flow view) | Cash flows from operating activities -124,533 ... Cash and cash equivalents at the end of period 98,650. |
| SI003 | LigaChem Biosciences | Financial Information - Consolidated Financial Statements (balance sheet view) | Total Assets 701,815 ... Total Liabilities 160,694 ... Total Equity 541,120. |
| SI004 | LigaChem Biosciences | Disclosure | Results of issuance (Voluntary Disclosure) ... [Revised] Decision on Paid-in Capital Increase ... [Revised] Decision on Issuance of Convertible Bonds ... LCB97 milestone technology fee receipt. |
| SI005 | LigaChem Biosciences | Stock | |
| SI006 | LigaChem Biosciences | Notice: Consolidated Financial Statements 2025 | |
| SI007 | LigaChem Biosciences | Shareholder notice on National Growth Fund direct investment | |
| SI008 | LigaChem Biosciences | Investor Q&A on National Growth Fund direct investment | This funding consists of 170 billion won in CB and 330 billion won in CPS, and no discount rate was applied. |
| SI009 | LigaChem Biosciences | Press release to shareholders on National Growth Fund direct investment | |
| SI010 | LigaChem Biosciences | Press release: two ADC technology transfer deals with Ono Pharmaceutical | Ono Pharmaceutical will pay up to $700 million in upfront, development, and sales milestones, with royalties after commercialization. |
| SI011 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Summary | Market Cap (intraday) 4.125T ... Q1 FY26 Revenue 35.89B Earnings -37.33B. |
| SI012 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Company Profile & Facts | It also sells medical device and supplies. |
| SI013 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Income Statement | Gross Profit 125,995,662.56 ... Operating Income -106,485,861.44. |
| SI014 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Cash Flow | Operating Cash Flow -124,532,936.67 ... End Cash Position 98,649,999.02. |
| SI015 | Yahoo Finance | LigaChem Biosciences Inc. (141080.KQ) Balance Sheet | Working Capital 460,349,830.55 ... Total Debt 12,643,935.24. |
| SI016 | Investing.com | LigaChem Biosciences (141080) Balance Sheet | Cash and Equivalents ... 98,650. |
| SI017 | Investing.com | LigaChem Biosciences Inc (141080) Cash Flow | Cash from Operations ... -124,532.94 ... Cash from Investing ... 94,141.31. |
| SI018 | Stockopedia | LigaChem Biosciences Income Statement (Aug 2026) | |
| SI019 | Bizhankook | Orion Continues Bio Bet Despite Widening Losses at LigaChem Biosciences | With losses widening and cash assets declining rapidly, LigaChem Biosciences is facing significant cash burn. |
| SI020 | Seoul Economic Daily | LigaChem Bio Gets Milestone as Ono Starts First Solid Tumor ADC Dosing | The exact amount is confidential ... but it corresponds to more than 10% of the company's consolidated revenue of 141.55307 billion won last year. |
| SI021 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund | The investment is structured as KRW 170 billion in convertible bonds and KRW 330 billion in convertible preferred shares, both with a 10-year maturity. |
| SI022 | BigGo Finance | South Korea's National Growth Fund Makes First Direct Investment in Biotech, Backing LigaChem Bio | The conversion price for both the CB and CPS is set at 149,300 won per share. |
| SI023 | Seedtable | LigaChem Biosciences Raises 323.0M USD in Growth Funding | The capital ... funds a strategic shift from pure out-licensing toward taking priority assets through late-stage trials and commercialization in-house. |
| SI024 | CHOSUNBIZ | Public Growth Fund backs LigaChem and approves LIG D&A investment in Korea | |
| SI025 | LigaChem Biosciences | About Us - Overview | |
| SI026 | LigaChem Biosciences | Partnerships | |
| SE001 | LigaChem Biosciences | About Us - Overview | LCB is focusing its R&D capabilities on the ADC and Immuno-Oncology drugs using next generation ADC platform. |
| SE002 | LigaChem Biosciences | Pipeline | Site-Specific Conjugation, Linker Stability, Efficient Toxin Release, PK profile. |
| SE003 | LigaChem Biosciences | ADC Pipeline | |
| SE004 | LigaChem Biosciences | Partnerships | |
| SE005 | LigaChem Biosciences | History | |
| SE006 | LigaChem Biosciences | Careers - Process | Required Documents: ... research statement ... Thesis abstract ... Recommendation letter from the academic advisor (preferred). |
| SE007 | LigaChem Biosciences | Careers - Our Culture | |
| SE008 | LigaChem Biosciences | Press release: SOT106 milestone and 2026 IND plan | SOT106 ... developed using LigaChem's ADC platform ... SOTIO intends to submit global IND application for SOT106 in the second half of 2026. |
| SE009 | LigaChem Biosciences | Press release: SOTIO milestone (Korean) | |
| SE010 | LigaChem Biosciences | Press release: strategic investment in Iksuda | IKSUDA currently possesses several promising oncology pipelines through multiple substance and platform technology transfers from LigaChem Bio. |
| SE011 | ClinicalTrials.gov API | NCT07460375 - LCB02A | LCB02A ... CLDN18.2-directed human monoclonal antibody linked to a topoisomerase I inhibiting payload. |
| SE012 | ClinicalTrials.gov API | NCT06774963 - LNCB74 | LNCB74 is an antibody drug conjugate ... IV in 21-day dosing cycles. |
| SE013 | ClinicalTrials.gov API | NCT05872295 - IKS014 | IKS014 is a human monoclonal antibody targeting HER2 linked to monomethyl auristatin F (MMAF). |
| SE014 | ClinicalTrials.gov API | NCT05365659 - IKS03 | IKS03 is a human monoclonal antibody targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug. |
| SE015 | National Cancer Institute | NCI Drug Dictionary - caxmotabart entudotin | site-specifically conjugated, via a tumor-selective beta-glucuronide linker, to ... MMAF. |
| SE016 | Experimental Hematology & Oncology | Advances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meeting | |
| SE017 | ADC Review | Advances in Bispecific and Novel Antibody-Drug Conjugates: Highlights from AACR 2026 | |
| SE018 | Frontiers in Oncology | Antibody–drug conjugate: a newly developed biological missile for tumor treatment | |
| SE019 | ChemExpress | Global ADC Landscape 2026H1 | |
| SE020 | BigGo Finance | South Korea's National Growth Fund Makes First Direct Investment in Biotech, Backing LigaChem Bio | The company has identified three core pipeline programs for accelerated direct development. |
| SE021 | Seoul Economic Daily | LigaChem Bio Secures 500 Billion Won Direct Investment from State Fund | |
| SE022 | Seoul Economic Daily | LigaChem Bio Gets Milestone as Ono Starts First Solid Tumor ADC Dosing | |
| SE023 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund | |
| SE024 | NextCure | Pipeline | LNCB74 has been specifically designed to reduce toxicity while improving tumor killing. |
| SE025 | Bizhankook | Orion Continues Bio Bet Despite Widening Losses at LigaChem Biosciences | |
| SU001 | LigaChem Biosciences | Partnerships | Accelerating global new drug development through joint research, co-development, and licensing with global partners. |
| SU002 | LigaChem Biosciences | History | |
| SU003 | LigaChem Biosciences | About Us - Overview | |
| SU004 | LigaChem Biosciences | ADC Pipeline | |
| SU005 | LigaChem Biosciences | Press release: SOT106 milestone and 2026 IND plan | LCB is eligible to receive upfront and potential milestone payments worth up to $1027.5 million ... plus royalties on net sales. |
| SU006 | LigaChem Biosciences | Press release: Iksuda strategic investment and pipeline expansion | |
| SU007 | LigaChem Biosciences | Press release: Ono package deal for LCB97 and ConjuAll platform | |
| SU008 | SOTIO Biotech | SOTIO expands ADC pipeline with exclusive collaboration and license agreement with LegoChem Biosciences | SOTIO will be responsible for the research, development, manufacturing and commercialization of the ADC products. |
| SU009 | Ono Pharmaceutical | Ono enters into license agreement for LCB97 and research collaboration to generate novel ADC candidates | Ono will have an exclusive worldwide right to develop, manufacture and commercialize LCB97 for solid tumors. |
| SU010 | NextCure | Pipeline | LNCB74 is currently in Phase 1 clinical development. |
| SU011 | Web Archive / Business Wire | LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC | LCB is eligible for up to potentially USD 1.7 billion in total consideration. |
| SU012 | Web Archive / Business Wire | Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 ADC programme from LegoChem Biosciences | The agreement provides Iksuda with exclusive world-wide rights (excluding Greater China and South Korea) to LCB’s Her2 ADC programme, LCB14. |
| SU013 | ClinicalTrials.gov API | NCT07460375 - LCB02A | |
| SU014 | ClinicalTrials.gov API | NCT06774963 - LNCB74 | |
| SU015 | ClinicalTrials.gov API | NCT05872295 - IKS014 | |
| SU016 | ClinicalTrials.gov API | NCT05365659 - IKS03 | |
| SU017 | BigGo Finance | National Growth Fund backs LigaChem Bio; 15 out-licensing deals through 2024 | Since its first technology transfer ... in 2015, LigaChem Bio has signed a total of 15 out-licensing deals through 2024, with cumulative technology export value reaching 9.6 trillion won. |
| SU018 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund | |
| SU019 | Seoul Economic Daily | LigaChem Bio Gets Milestone as Ono Starts First Solid Tumor ADC Dosing | |
| SU020 | Seoul Economic Daily | LigaChem Bio Secures 500 Billion Won Direct Investment from State Fund | |
| SU021 | Bizhankook | Orion Continues Bio Bet Despite Widening Losses at LigaChem Biosciences | |
| SU022 | National Cancer Institute | NCI Drug Dictionary - caxmotabart entudotin | |
| SU023 | LigaChem Biosciences | Iksuda initiates HER2-ADC (LCB14/IKS014) Phase 1 trial | Fosun Pharma holds the licence to the ADC in Greater China where it is designated FS-1502. |
| SU024 | CStone Pharmaceuticals | First patient enrolled in the global multicenter Phase 1b clinical trial of CS5001 (ROR1 ADC) | In October 2020, CStone signed a licensing agreement with LigaChem Biosciences ... Under the agreement, CStone obtains the exclusive global right to develop and commercialize CS5001 outside the Republic of Korea. |
| SU025 | LigaChem Biosciences | LCB71 (ROR1 ADC), CStone Phase1a result in solid tumors and lymphomas | |
| SR001 | LigaChem Biosciences | Disclosure | Material Management Information related to Judgment of Investment(LNCB74(B7H4-ADC) 단독 개발 및 기술이전 권리 확보) |
| SR002 | LigaChem Biosciences | ESG Governance | As of the end of December 2023, the Company’s board of directors consists of three inside directors and two outside directors. |
| SR003 | LigaChem Biosciences | Leadership | Scientific Advisory Board ... ADC Toxicology·Safety ... ADC Manufacturing·CMC |
| SR004 | LigaChem Biosciences | History | |
| SR005 | LigaChem Biosciences | Careers - Process | Required Documents ... research statement ... Thesis abstract ... Recommendation letter from the academic advisor. |
| SR006 | LigaChem Biosciences | Financial Information - Balance Sheet | |
| SR007 | LigaChem Biosciences | Financial Information - Income Statement | |
| SR008 | LigaChem Biosciences | Financial Information - Cash Flow | |
| SR009 | BigGo Finance | National Growth Fund backs LigaChem Bio and outlines late-stage spending plan | |
| SR010 | Bizhankook | Orion Continues Bio Bet Despite Widening Losses at LigaChem Biosciences | |
| SR011 | Seoul Economic Daily | LigaChem Bio Secures 500 Billion Won Direct Investment from State Fund | |
| SR012 | Seoul Economic Daily | LigaChem Bio Gets Milestone as Ono Starts First Solid Tumor ADC Dosing | |
| SR013 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund | |
| SR014 | ClinicalTrials.gov API | NCT07460375 - LCB02A | |
| SR015 | ClinicalTrials.gov API | NCT06774963 - LNCB74 | |
| SR016 | ClinicalTrials.gov API | NCT05872295 - IKS014 | |
| SR017 | ClinicalTrials.gov API | NCT05365659 - IKS03 | |
| SR018 | Frontiers in Oncology | Antibody–drug conjugate: a newly developed biological missile for tumor treatment | |
| SR019 | Experimental Hematology & Oncology | Advances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meeting | |
| SR020 | ADC Review | Advances in Bispecific and Novel Antibody-Drug Conjugates: Highlights from AACR 2026 | |
| SR021 | Google Patents | US10383949B2 - Compounds comprising self-immolative group | Current Assignee ... Ligachem Biosciences Inc ... Legal status ... Active |
| SR022 | Google Patents | US11413353B2 - Conjugates comprising self-immolative groups and methods related thereto | Current Assignee ... Ligachem Biosciences Inc ... Active, expires 2039-11-11 |
| SR023 | Google Patents | US10407743B2 - Site-specific conjugation of linker drugs to antibodies and resulting ADCs | Family has litigation |
| SR024 | SOTIO Biotech | SOTIO expands ADC pipeline with exclusive collaboration and license agreement with LegoChem Biosciences | |
| SR025 | Ono Pharmaceutical | Ono enters into license agreement for LCB97 and research collaboration to generate novel ADC candidates | |
| SR026 | NextCure | Pipeline | |
| SR027 | CStone Pharmaceuticals | First patient enrolled in the global multicenter Phase 1b clinical trial of CS5001 | |
| SR028 | LigaChem Biosciences | Iksuda strategic investment and pipeline expansion | |
| SR029 | LigaChem Biosciences | SOT106 milestone and IND plan | |
| SR030 | LigaChem Biosciences | LCB71 / CS5001 Phase 1a result in solid tumors and lymphomas | |
| SR031 | LigaChem Biosciences | Iksuda initiates HER2-ADC (LCB14/IKS014) Phase 1 trial | |
| SR032 | Web Archive / Business Wire | LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC | |
| SR033 | Google Patents | WO2017089890A1 - Conjugates comprising self-immolative groups and methods related thereto | |
| SR034 | Google Patents | US20200297865A1 - Conjugates comprising self-immolative groups and methods related thereto | |
| SR035 | Google Patents | US20170080103A1 - Site-specific conjugation of linker drugs to antibodies and resulting ADCs | |
| SR036 | Korea Exchange | Disclosure search for Ligachem | |
| SR037 | ClinicalTrials.gov | Search results for Ligachem | |
| SV001 | LigaChem Biosciences | Disclosure | |
| SV002 | LigaChem Biosciences | Financial Information - Income Statement | |
| SV003 | LigaChem Biosciences | Financial Information - Cash Flow | |
| SV004 | Yahoo Finance | LigaChem Biosciences Inc. quote | Market Cap (intraday) 4.125T ... 1y Target Est 211,666.67 |
| SV005 | Yahoo Finance | LigaChem Biosciences analyst ratings, estimates & forecasts | Current Year (2026) Avg. Estimate 284B ... Next Year (2027) Avg. Estimate 286.48B |
| SV006 | BigGo Finance | National Growth Fund backs LigaChem Bio and outlines late-stage spending plan | |
| SV007 | Seoul Economic Daily | LigaChem Bio Secures 500 Billion Won Direct Investment from State Fund | |
| SV008 | Bizhankook | Orion Continues Bio Bet Despite Widening Losses at LigaChem Biosciences | |
| SV009 | WOWTALE | LigaChem Biosciences Secures $357 Million From Korea National Growth Fund | |
| SV010 | Ono Pharmaceutical | Ono enters into license agreement for LCB97 and research collaboration to generate novel ADC candidates | |
| SV011 | SOTIO Biotech | SOTIO expands ADC pipeline with exclusive collaboration and license agreement with LegoChem Biosciences | |
| SV012 | NextCure | Pipeline | |
| SV013 | CStone Pharmaceuticals | First patient enrolled in the global multicenter Phase 1b clinical trial of CS5001 | |
| SV014 | ClinicalTrials.gov API | NCT07460375 - LCB02A | |
| SV015 | ClinicalTrials.gov API | NCT06774963 - LNCB74 | |
| SV016 | ClinicalTrials.gov API | NCT05872295 - IKS014 | |
| SV017 | ClinicalTrials.gov API | NCT05365659 - IKS03 | |
| SV018 | Frontiers in Oncology | Antibody–drug conjugate: a newly developed biological missile for tumor treatment | |
| SV019 | Experimental Hematology & Oncology | Advances in antibody-drug conjugates in cancer: latest updates from the 2026 AACR annual meeting | |
| SV020 | Google Patents | US11413353B2 - Conjugates comprising self-immolative groups and methods related thereto | |
| SV021 | Google Patents | US10383949B2 - Compounds comprising self-immolative group | |
| SV022 | Yahoo Finance | ADC Therapeutics SA quote | |
| SV023 | CompaniesMarketCap | ADC Therapeutics market capitalization | |
| SV024 | Yahoo Finance | Sutro Biopharma quote | |
| SV025 | CompaniesMarketCap | Sutro Biopharma market capitalization | |
| SV026 | Yahoo Finance | CStone Pharmaceuticals quote | |
| SV027 | Pfizer | Pfizer completes acquisition of Seagen | |
| SV028 | AbbVie | AbbVie completes acquisition of ImmunoGen | |
| SV029 | LigaChem Biosciences | Iksuda strategic investment and pipeline expansion | |
| SV030 | Web Archive / Business Wire | LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC |